Agency of the United States Department of Health and Human Services
POPULARITY
Categories
469 episodes with fda
421 episodes with fda
300 episodes with fda
401 episodes with fda
208 episodes with fda
256 episodes with fda
145 episodes with fda
195 episodes with fda
195 episodes with fda
131 episodes with fda
107 episodes with fda
73 episodes with fda
199 episodes with fda
55 episodes with fda
84 episodes with fda
85 episodes with fda
72 episodes with fda
75 episodes with fda
143 episodes with fda
94 episodes with fda
66 episodes with fda
68 episodes with fda
135 episodes with fda
150 episodes with fda
111 episodes with fda
247 episodes with fda
61 episodes with fda
77 episodes with fda
52 episodes with fda
37 episodes with fda
104 episodes with fda
47 episodes with fda
47 episodes with fda
121 episodes with fda
100 episodes with fda
97 episodes with fda
73 episodes with fda
95 episodes with fda
73 episodes with fda
71 episodes with fda
50 episodes with fda
66 episodes with fda
44 episodes with fda
45 episodes with fda
53 episodes with fda
50 episodes with fda
69 episodes with fda
67 episodes with fda
85 episodes with fda
66 episodes with fda
38 episodes with fda
57 episodes with fda
54 episodes with fda
99 episodes with fda
Check out host Bidemi Ologunde's new show: The Work Ethic Podcast, available on Spotify and Apple Podcasts.Email: bidemiologunde@gmail.comIn this episode, host Bidemi Ologunde connects the dots between three fast-moving signals from Feb 23–Mar 1, 2026: a chokepoint-driven escalation in the US/Israel/Iran war, Europe's shift from "paper sanctions" to physical interdictions at sea, and the growing reality that grids and courtrooms are now battlegrounds. What does it mean when the Strait of Hormuz becomes a frontline? Are maritime seizures the new normal in sanctions enforcement, and what happens when states push back in the gray zone? Can international law and infrastructure strikes reshape alliances faster than diplomats can react? Plus: what should listeners watch next as markets, militaries, and legal institutions collide in real time?On the Bid Picture Podcast, I talk about big ideas, and Lembrih is one of them. Born from Ghanaian roots, Lembrih is building an ethical marketplace for Black and African artisans: makers of heritage-rich products often overlooked online. The vision is simple: shop consciously, empower communities, and share the stories behind the craft. Lembrih is live on Kickstarter now, and your pledge helps build the platform. Visit lembrih.com, or search “Lembrih” on Kickstarter.Sponsors and partners:Promeed: 100% mulberry silk pillowcases and bedding that feel incredibly soft, stay breathable, and are naturally gentle on hair and skin.SurviveX: professional-grade FSA/HSA eligible first aid and preparedness kits designed in Virginia, USA and produced in an FDA-registered facility.Support the show
The Middle East faces a major geopolitical shift following a joint U.S. and Israeli operation in Iran that resulted in the death of Supreme Leader Ayatollah Ali Khamenei and several top commanders. President Trump ordered the strike with the goal of "giving the country back to the Iranian people," sparking debate in Washington over executive authority and the War Powers Act. Texas Republican Congressman Pat Fallon, a member of the Armed Services and Intelligence Committees, joins the Rundown to discuss the strategic implications of the attack, and the risk of retaliation at home. With 30 million Americans living with a rare disease, is the traditional "blockbuster" drug model failing the approximately one in 11 people who need specialized care? Judy Stecker, founder of Wheeler's Warriors and former HHS official, joins us to discuss a historic shift at the FDA. From the groundbreaking use of genome editing to treat metabolic diseases to the emotional journey of her son Wheeler, Stecker explains how she believes the science of "genetic patches" has finally outpaced our regulatory system. Plus, commentary by Senior Fellow at the Lexington Institute, Dr. Rebecca Grant. Learn more about your ad choices. Visit podcastchoices.com/adchoices
It's Endometriosis Awareness Month. Ali's guest this week, Holly Abel, was eleven years old when her debilitating periods started. For decades, doctors told her it was “normal.” That she was dramatic. Hormonal. Sensitive. It wasn't normal. In early 2023, Holly was finally diagnosed with severe stage 4 endometriosis — affecting multiple organs throughout her body. Shortly after, she experienced a miscarriage. In December 2023, she underwent major surgery. Then in March 2024, after a routine HSG, everything began to unravel. By early May, she was in septic shock and given a 10% chance to live. In July, a total hysterectomy saved her life… and ended her ability to carry children. Holly talks about all of this and more in an educational, emotional episode about medical trauma, advocacy and survival. EPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe 3-book bundle is now just $49 (normally $79)!The latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.PHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.BELIIG: @belibabywww.belibaby.com Are you thinking about growing your family? Whether you're just starting to plan or are actively trying to conceive, preconception health is key. Beli has vitamins to help both women and men optimize their health before pregnancy. With essential nutrients like Folate, Iodine, and Zinc, Beli ensures your body is ready for this exciting next step. Give yourself and your future baby the best foundation for a healthy start.Visit Belibaby.com today and use code IAF15 for 15% off your first order. Our Sponsors:* Sign up and get 10% off at BetterHelp dot com. Your emotional wellbeing matters. Find support and feel lighter in therapy. Support this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
In this episode, Caroline hosts renowned plastic surgeon and star of Botched, Dr. Terry Dubrow, for a “hard questions” episode and some laughs. He educates us on Ozempic/GLP-1 drugs, microdosing, and newer peptide options like tirzepatide and the not-yet–FDA-approved “retatrutide,” which he says may help lower inflammation and support “preservation longevity” while AI accelerates disease breakthroughs. They discuss fears around AI, his belief that people should learn to use it, and his warning about unregulated online/black-market compounds. In beauty, Dubrow urges women to dial back fillers, avoid “Ozempic face panic,” be cautious with deep plane facelifts, and invest more in consistent energy devices (lasers/ultrasound/radiofrequency) rather than extreme procedures. He shares lessons from Botched and Plastic Surgery Rewind, including turning down risky patients, a memorable case removing “concrete” facial injections by reducing—not fully removing—masses, and how he and his wife test wellness trends on their “Doctor and Mrs. Guinea Pig” channel. He also covers peptides uncertainty, cycling use if someone insists, creatine findings, daily visualization, and marriage rules for handling conflict.Find Dr Dubrow - Website: www.drdubrow.com- Instagram: @drdubrow- TikTok: @drterrydubrow- Botched Presents: Plastic Surgery Rewind on E! and PeacockFollow Caroline:- Podcast: https://being-caroline.com/podcast/- IG: https://www.instagram.com/shop.with.caroline/- TikTok: https://www.tiktok.com/@shop.with.caroline- Facebook: https://www.facebook.com/beingcaroline- Search Looks: https://www.shop-with-caroline.com/- Shop New Merch: https://shop.dearmedia.com/collections/coming-in-hotPlease note that this episode may contain paid endorsements and advertisements for products and services. Individuals on the show may have a direct or indirect financial interest in products or services referred to in this episode.Sponsors:Text HOT to 64000 to get twenty percent off all IQBAR products, plus FREE shipping. Message and data rates may apply.Produced by Dear Media.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Contributor: Taylor Lynch MD Educational Pearls: Melatonin is an endogenous hormone released primarily by the pineal gland Also released by extrapineal regions in the retina, the GI tract, and some immune cells Peak secretion occurs at night and is suppressed during the day Secretion and production decrease with age Older patients experience the greatest improvement in sleep latency and sleep quality Mechanism of action in the suprachiasmatic nucleus of the hypothalamus MT1 receptor Reduces normal firing MT2 receptor Shifts the circadian rhythm FDA approved for insomnia Decreases sleep latency by 7 minutes Increases total sleep time by 8 minutes FDA approved for circadian sleep-wake disorders Jet lag Most effective in west-to-east travel Best if crossing at least 5 time zones Shift work A study examined ED physicians and nurses with rotating shifts Modest increase in deep sleep percentage No difference in cognition or reaction time the day after taking melatonin Nurses on rotating night shifts experienced increased total sleep time by 20 minutes Dosing 0.5 - 3 mg is the most evidence-based dosing Higher doses increase the risk of rebound grogginess but do not improve outcomes References Ahmad SB, Ali A, Bilal M, et al. Melatonin and Health: Insights of Melatonin Action, Biological Functions, and Associated Disorders. Cell Mol Neurobiol. 2023;43(6):2437-2458. doi:10.1007/s10571-023-01324-w Herxheimer A, Petrie KJ. Melatonin for the prevention and treatment of jet lag. Cochrane Database Syst Rev. 2002;(2):CD001520. doi:10.1002/14651858.CD001520 Morgenthaler TI, Lee-Chiong T, Alessi C, Friedman L, Aurora RN, Boehlecke B, Brown T, Chesson AL Jr, Kapur V, Maganti R, Owens J, Pancer J, Swick TJ, Zak R; Standards of Practice Committee of the American Academy of Sleep Medicine. Practice parameters for the clinical evaluation and treatment of circadian rhythm sleep disorders. An American Academy of Sleep Medicine report. Sleep. 2007 Nov;30(11):1445-59. doi: 10.1093/sleep/30.11.1445. Erratum in: Sleep. 2008 Jul 1;31(7):table of contents. PMID: 18041479; PMCID: PMC2082098. Thottakam BMVJ, Webster NR, Allen L, Columb MO, Galley HF. Melatonin Is a Feasible, Safe, and Acceptable Intervention in Doctors and Nurses Working Nightshifts: The MIDNIGHT Trial. Front Psychiatry. 2020;11:872. Published 2020 Aug 27. doi:10.3389/fpsyt.2020.00872 Summarized and edited by Jorge Chalit, OMS4 Donate: https://emergencymedicalminute.org/donate/ Join our mailing list: http://eepurl.com/c9ouHf
Pharma ads, biotech IPOs, $1M longevity programs, oh my!This month's Digital Health Download skews towards biotech, which is having a moment. Tune in to hear Halle and Michael cover the latest headlines.We cover:Why pharma ads are surging and the growing push for restrictions on D2C drug advertisingHims & Hers' $1.15B acquisition of Eucalyptus, its global expansion strategy, and the FDA crackdown on compounded GLP‑1 drugsThe return of biotech IPOs, with Eikon Therapeutics and Generate Biomedicines signaling investor interest in platform‑based drug discoveryVaccine makers scaling back research amid policy uncertainty, declining uptake, and tighter fundingTrumpRx's “most favored nation” drug pricing approach, and what one STAT analysis foundBryan Johnson's $1M per year “Immortals” longevity program—Show notes:Should drug companies be advertising to consumers? (The New York Times) Hims & Hers Enters $1.15 Billion Agreement to Acquire Eucalyptus (PharmExec.com)A sign biotech is back? Four drugmakers go public, raising nearly $1 billion in all (STAT)Vaccine Makers Curtail Research and Cut Jobs (The New York Times) TrumpRx claims to offer the lowest prices. But many drugs have cheaper generics (STAT)Bryan Johnson's Immortals: $1M to try longevity regimen (Axios) —"Halle Tecco wanted to see tech used for better medical services and getting people engaged in their own health. Now, she's written a book on how she went about it." - The WSJMassively Better Healthcare is out now!—Rock Health's annual CEO Summit is returning to the New York Stock Exchange on March 27th! Learn more and nominate a CEO to join this invite-only event here. —
In this episode, I shares the real story behind building a sustainable hard-goods brand in the pet industry, unpacking the engineering, manufacturing, certification, and financial trade-offs that most people never see. From design constraints and material decisions to B Corp, 1% for the Planet, and sustainability reporting, this is an honest founder-level look at what it actually takes to balance environmental ambition with business reality, and why sustainability is a discipline, not a label.Timestamps to relevant points within the episode, use this format:[00:00] The Question Most Consumers Never Ask[02:10] From Sustainability Advisor to Bootstrapped Founder[04:45] Progress vs Perfection in Sustainable Business[07:30] The 4-Pillar Sustainability Framework (Environment, People, Economy, Culture)[10:15] Why Sustainability Lives in Engineering Constraints[12:00] Designing for Longevity (And the Business Model Tension)[14:20] Care-Centered Design & Piper's Physiotherapy Moment[16:30] Material Trade-Offs: Why Bamboo Wasn't the Right Choice[19:00] Certifications Explained: What Actually Matters[21:30] 1% for the Planet & Financial Accountability[23:10] FSC Packaging, REACH & Compliance[24:45] B Corp: Why It's Not a Day One Certification[26:30] Sustainability Reporting & Measurement[27:40] Why Profit Is Oxygen in Sustainable Business[29:00] Celebrating Brands That Are Doing the Work[30:00] Final Thoughts & Community InvitationLinks from the episodes:1% for the PlanetPrevious Mama Earth Talk Episode with the CEO of 1% for the Planet, Kate WilliamsPet Sustainability CoalitionB Corp CertificationForest Stewardship Council (FSC) ISO 14001 Environmental Management SystemsCradle to Cradle CertificationMama Earth Talk Online CourseKey Takeaways:• Sustainable product development is not theoretical, it's constrained by tooling costs, manufacturing realities, minimum order quantities, and cash flow.• A structured sustainability framework (Environment, People, Economy, Culture) is your decision-making filter when trade-offs get hard.• Perfection can become paralysis, progress with sequencing is often more impactful than waiting for “100% sustainable.”• Sustainability in hard goods lives in engineering decisions, not marketing language.• Designing for longevity reduces waste, but can reduce repeat purchases. That's a business model tension founders must face.• The “most sustainable-looking” material isn't always the most appropriate one. Context matters.• Certifications are validation layers, not starting point, they should align with operational readiness and financial stability.• Material compliance (FDA, REACH, BPA-free) is foundational and often more important than flashy badges.• Sustainability reporting turns intention into measurement, and measurement drives accountability.• Profit isn't the enemy of sustainability, it's oxygen. Without financial viability, environmental ambition can collapses.• Transparency builds trust when it shows process, not perfection.• Celebrating brands that are doing the structural work shifts incentives across the industry.• Sustainability isn't a label, it's an ongoing discipline.
Is raw milk actually safe—and could new technology change everything we thought we knew? On this episode of The Tudor Dixon Podcast, Tudor sits down with Bob Comstock, founder and CEO of Tamarack Biotics, to break down the growing debate around raw milk, its health benefits, and the real risks consumers need to understand. While raw milk has long been praised for its immune-boosting and allergy-fighting properties, it also carries serious safety concerns due to harmful bacteria. So is there a way to get the benefits without the danger? Bob Comstock explains how UV pasteurization—a groundbreaking, FDA-reviewed technology—can eliminate pathogens while preserving the bioactive nutrients that traditional heat pasteurization destroys. The result? A potential future where milk supports stronger immune systems, improved gut health, and even reduced chronic disease risk. In this episode, Tudor and Bob discuss: The truth about raw milk: benefits vs. risks How UV pasteurization works (and why it’s different) The connection between dairy, gut health, and chronic disease New research on allergies, immune function, and nutrition What FDA approval means—and how soon this could hit store shelves Why this innovation could reshape food, healthcare, and the dairy industry From parents concerned about food safety to anyone interested in nutrition and health policy, this is a fascinating look at how “food as medicine” could become reality.
Check out host Bidemi Ologunde's new show: The Work Ethic Podcast, available on Spotify and Apple Podcasts.Email: bidemiologunde@gmail.comIn this episode, host Bidemi Ologunde unpacks the rise of "nihilistic" violence, where ideology can be thin, but the drive for notoriety, cruelty, and chaos is the point. How do online subcultures turn despair into a violent aesthetic? Why do these spaces sometimes overlap with accelerationist and neo-Nazi ecosystems without being the same thing? And what do documented cases suggest about a disturbing crime–terror convergence, including sextortion and coercion targeting young people? The episode closes with practical, prevention-focused takeaways, and how to cover these stories without amplifying propaganda or "how-to" harm.Quick question: when you buy something handmade, do you ever wonder who made it, and where your money really goes? Lembrih is building a marketplace where you can shop Black and African-owned brands and learn the story behind the craft. And the impact is built in: buyers can support vendors directly, and Lembrih also gives back through African-led charities, including $1 per purchase. They're crowdfunding on Kickstarter now. Back Lembrih at lembrih.com, or search “Lembrih” on Kickstarter.Sponsors and partners:Promeed: 100% mulberry silk pillowcases and bedding that feel incredibly soft, stay breathable, and are naturally gentle on hair and skin.SurviveX: professional-grade FSA/HSA eligible first aid and preparedness kits designed in Virginia, USA and produced in an FDA-registered facility.Support the show
In this episode, Dr. K discusses a growing concern in the mental health field: the potential for intensive AI use to trigger severe crises like psychosis, suicidality, and homicidality. He examines a chilling case study that suggests AI might act more like a drug than a simple tool, and he challenges the tech industry's claims regarding user safety. What to expect in this episode: The AI-Psychosis Connection: An analysis of a case study where a 26-year-old with no history of psychosis became hospitalized twice due to extensive chatbot use. AI as a "Digital Drug": Why AI-induced mental health symptoms often resolve immediately after stopping use, mirroring the effects of substances like synthetic marijuana. Challenging the "Vulnerability" Argument: A critical look at why tech leaders claim only "at-risk" people are affected—despite not actually measuring user risk factors or medical history. The Lack of Safety Regulation: Why AI companies aren't regulated by the FDA and the dangers of launching products without formal clinical trials for mental health impacts. The 20-Year Warning: Advice on why users need to be cautious about their digital habits today, as definitive scientific answers may take decades to arrive. HG Coaching : https://bit.ly/46bIkdo Dr. K's Guide to Mental Health: https://bit.ly/44z3SztHG Memberships : https://bit.ly/3TNoMVf Products & Services : https://bit.ly/44kz7x0 HealthyGamer.GG: https://bit.ly/3ZOopgQ Learn more about your ad choices. Visit megaphone.fm/adchoices
On this episode of Vitality Radio, Jared breaks down practical, real-world Biocidin protocols used in functional medicine settings to support microbial balance, gut health, sinus health, and post-antibiotic recovery. Learn how practitioners commonly layer botanicals, binders, probiotics, and liver support to help maintain a healthy terrain and resilient microbiome. Jared explains how different forms of Biocidin are used for oral microbiome support, sinus and upper respiratory balance, gut and SIBO concerns, and rebuilding after antibiotic use. He also shares guidance on timing, layering, and supporting detox and drainage pathways for more effective results. Buy ONE Biocidin or Dentalcidin product plus ONE or more products from the Biocidin Protocol Collection and get 20% off automatically in your cart through 3/28/26.Additional Information:#555: From Gut to Gums: Mastering Microbial Balance Using Biocidin with Dr. Shawn Manske#616: Microbiome Balance from Mouth to Gut: Foundations of Clearing and Rebuilding with Biocidin – Part 1Biocidin Protocol Blog PostVisit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
The Derm on RheumNow podcast is a collection of Citations and Content curated for dermatologists – addressing Psoriasis, PsA, CLE, vasculitis, HS, other CTD skin disorders. dermatology drugs, biiologics, JAKs - their use, efficacy and side effects. Features Dr. Jack Cush, Editor at RheumNow.com. SHOW NOTES FDA sent a complete response letter to AstraZeneca on their application (BLA) for anifrolumabs (Saphnelo) subcutaneous use in SLE. Despite a positive TULIP-SC trial & EU approval of SC-anifrolumab, FDA & sponsor still have to work things out. CRL reasons are unknown https://t.co/3dNwEyolrj Review of Calcinosis Cutis - Surgical intervent. most effective (excision, curettage, laser ablation, etc). Medical measures inconsistently, partially effective, best if used early & localized (CCB, TCN, probenecid, immunomodulation, biologics, colchicine, NA thiosulfate, & JAKi https://t.co/rv0hQBv6nX Systematic Review of Targeted Rx for Systemic Sclerosis: from 32 RCTs & 2036 pts Rx w/ 23 targeted agents. Guselkumab had greatest effect on mRSS, followed by tofacitinib, inebilizumab, & baricitinib. For FVC, B-cell Rx (belimumab, RTX) had highest efficacy https://buff.ly/vHOSRws Dermatomyositis outcomes w/ 2475 pts (claims) & 1196 pts (EHR). Half had myositis panels & 35% had + MSAbs. Steroid use common in 69% & 74%. HCQ, MTX, MMF. Outocmes (per 1000PYs) wereL all-cause hospitalisation 92, malignancy 15.3, ILD 6.4, and myocarditis 2.1 https://t.co/DJqKGNGX76 Danish DERMBIO registry of psoriasis pts Rx w/ biologics. Among 3790 bionaive pts ustekinumab had best 1-5 yr survival vs (ADA & SEC). In 3403 bioexperienced pts, bimekizumab, guselkumab, & risankizumab had highest 2-year drug survival rate. https://t.co/TInyLPMYkb Real-world study of 1202 #PsA pts shows that secukinumab retention rates were lower w/ smoking (79%/73%/72% in never/former/current smokers) but not w/ obesity (72%/77%/77% in normal/overweight/obese), Adh HR signif. higher w/ former (1.32) & current smokers (1.27) https://t.co/1REWmod73W Together PSO Trial - Combination Ixekizumab and Tirzepatide Today Lilly announced top line results of the TOGETHER-PsO open-label, Phase 3b trial demonstrating the significant benefits of concomitant ixekizumab (IXE: an IL-17A inhibitor) and tirzepatide (TIR: GLP-1agonist) over https://t.co/YWCjN2NyGM
In Episode 46 of OnlyLands, hosted by a full-blown menagerie of Badlands Media hosts, the chaos is immediate and relentless. Zak kicks things off with a nightmare roof leak involving solar panels, bankrupt warranties, and a bathroom exhaust vent that was never actually vented. From there, the crew spirals into FDA “allowable maggots,” pigeon-infused cornstarch processing, and whether beard oil might secretly be an aphrodisiac. They dissect Bill Clinton's carefully worded Epstein testimony, debate whether Gavin Newsom's awkward pandering was racist or just condescending, and question why public trust keeps collapsing at every institutional level. There's a deep dive into taxation, borrowing, and Spooner's eternal relevance, plus a detour into marble music machines and spinning-neck guitars. It's equal parts philosophy, comedy, conspiracy, and beard maintenance. As always, nothing is safe — not politicians, not Neanderthals, and definitely not boar bristle brushes.
This week's stories: Sinclair's This Is the Test: Are we about to see age reversal in humans? At the World Governments Summit 2026 in Dubai, Harvard geneticist David Sinclair told world leaders that ageing could soon be reversible and said the first human clinical trials of epigenetic reprogramming therapies are moving forward. The core idea is that ageing is partly an information problem, how cells read DNA, not just cumulative damage, and that partial reprogramming could restore youthful function without turning tissues into tumors. Dave frames this as a rare binary moment for longevity: either early, localized human trials (starting with tightly controlled tissue targets like the eye) show meaningful functional rejuvenation with acceptable safety, or the field has to recalibrate fast. Either way, the next couple of years will heavily influence where money, regulators, and serious researchers place their bets. • Sources: – World Governments Summit: https://www.worldgovernmentssummit.org/media-hub/news/detail/ageing-could-soon-be-reversible-says-harvard-scientist-at-wgs-2026 – NAD / Life Biosciences coverage: https://www.nad.com/news/fda-greenlights-life-biosciences-human-study-setting-up-pivotal-test-for-aging-theory-from-harvards-david-sinclair AlphaFold 4 in a locked box: DeepMind's private AI drug design engine Isomorphic Labs, DeepMind's drug discovery company, unveiled a proprietary drug design engine that outside scientists are comparing to an AlphaFold 4 moment, but for designing drugs, not just predicting structures. The big shift is that this system is closed: no public weights, no open database, and access appears to flow through partnerships with pharma companies. Dave breaks down why that matters for the longevity world: if AI makes early discovery cheaper and faster, we might see more serious shots on ageing targets over the next decade, but a closed model can also mean less transparency, bigger IP moats, and no guarantee that faster discovery leads to cheaper drugs. • Sources: – Nature: https://www.nature.com/articles/d41586-026-00365-7 – Isomorphic Labs: https://www.isomorphiclabs.com/articles/the-isomorphic-labs-drug-design-engine-unlocks-a-new-frontier Peptides in the freezer: El Mencho's anti aging stash and the dark side of wellness After reports and images from the final hideout linked to Jalisco New Generation Cartel leader Nemesio Oseguera Cervantes (El Mencho), coverage highlighted a detail that feels uncomfortably familiar to anyone in the modern wellness internet: injectable vials stored in a freezer with a schedule attached, including Tationil Plus, a glutathione based injectable marketed in some places for “cellular health,” cosmetic effects, and anti ageing. Dave uses the absurdity as a narrative wedge, not cartel gossip, to talk about how normalized gray market injectables have become, and how marketing (“detox,” “cellular reset”) often outruns evidence and safety. The segment pivots into a practical filter: which compounds are real therapeutics under medical supervision, and which are expensive folklore with sourcing risk and unknown long term downsides. • Sources: – New York Post: https://nypost.com/2026/02/25/world-news/inside-the-luxurious-love-nest-where-mexican-drug-lord-el-mencho-spent-his-final-days/ – Sky News (Reuters photos referenced): https://news.sky.com/story/inside-the-mexican-villa-where-feared-drug-lord-el-mencho-spent-final-hours-13511954 – Reuters photo gallery: https://www.reuters.com/pictures/el-menchos-last-hideout-inside-villa-where-cartel-leader-spent-final-hours-2026-02-25/W7DK5WEXS5IMLLZQO2P3CXGXFM The disease we thought was dead: measles comes roaring back Measles cases have surged in early 2026, with reporting citing at least 588 cases in the U.S. by late January, already more than many full year totals, and additional updates showing continued acceleration into February. Dave reframes this as a healthspan floor issue: you can argue about peptides and mitochondria all day, but measles is so contagious that once community immunity drops, outbreaks move fast and hit the most vulnerable first, especially infants and immunocompromised people. He also flags the systems problem: many clinicians have never seen measles, which increases the odds of delayed recognition and wider exposure in waiting rooms. The actionable move is boring and high ROI: verify MMR status for you and your family and close gaps before outbreaks get closer to home. • Sources: – AMA Morning Rounds (Week of Feb. 2, 2026): https://www.ama-assn.org/about/publications-newsletters/top-news-stories-ama-morning-rounds-week-feb-2-2026 – ABC News (CDC case count coverage): https://abcnews.com/Health/588-us-measles-cases-reported-january-cdc/story?id=129699078 – CIDRAP (case tracking context): https://www.cidrap.umn.edu/measles/us-measles-cases-soar-588-so-far-year-south-carolina-confirms-58-new-infections DC vs your health: Trump's State of the Union health reset President Donald Trump's 2026 State of the Union included a cluster of healthcare themes that function as a directional signal for agencies and payers this year, including drug pricing rhetoric, price transparency, and broader coverage and affordability framing. Dave translates the politics into a practical heuristic for biohackers: federal posture quietly determines what becomes easy versus painful to access in the legitimate system, from GLP 1 coverage rules and prior auth behavior to how friendly the environment is for telehealth, at home diagnostics, and eventually whatever “real longevity medicine” looks like. You do not need every policy detail in a weekly rundown, just the weather report: reimbursement and enforcement trends shape what stays niche, what scales, and what gets friction. • Sources: – Advisory Board: https://www.advisory.com/daily-briefing/2026/02/25/health-policy-roundup – Healthcare Dive: https://www.healthcaredive.com/news/trump-state-of-the-union-healthcare-2026/812962/ – This Week in Public Health analysis: https://thisweekinpublichealth.com/blog/2026/02/25/the-2026-state-of-the-union-what-it-means-for-health-and-public-health/ All source links are provided for direct access to the original reporting and research. This episode is designed for biohackers, longevity seekers, and high-performance listeners who want mechanism-level clarity on circadian biology, neurodegeneration signals, cognitive training, caffeine strategy, and supplement regulation. Host Dave Asprey connects emerging science, behavioral data, and policy shifts into practical frameworks you can use to build a resilient, adaptable health stack. New episodes every Tuesday, Thursday, Friday, and Sunday. Keywords: David Sinclair age reversal, epigenetic reprogramming therapy, Yamanaka factors OSK, Life Biosciences clinical trial, human rejuvenation trial 2026, biological age reset, longevity breakthrough news, DeepMind Isomorphic Labs, AlphaFold 4 drug design, AI drug discovery engine, geroprotective drug development, peptide gray market risks, injectable glutathathione Tationil Plus, GLP-1 regulation FDA warning, wellness industry regulation, measles outbreak 2026 US, MMR vaccine status adults, vaccine trust public health, health policy 2026 State of the Union, GLP-1 access and reimbursement, telehealth longevity care, biohacking news, anti-aging research update Thank you to our sponsors! Resources: • Get My 2026 Clean Nicotine Roadmap | Enroll for free at https://daveasprey.com/2026-clean-nicotine-roadmap/ • Get My 2026 Biohacking Trends Report: https://daveasprey.com/2026-biohacking-trends-report/ • Dave Asprey's Latest News | Go to https://daveasprey.com/ to join Inside Track today. • Danger Coffee: https://dangercoffee.com/discount/dave15 • My Daily Supplements: SuppGrade Labs (15% Off) • Favorite Blue Light Blocking Glasses: TrueDark (15% Off) • Dave Asprey's BEYOND Conference: https://beyondconference.com • Dave Asprey's New Book – Heavily Meditated: https://daveasprey.com/heavily-meditated • Join My Substack (Live Access To Podcast Recordings): https://substack.daveasprey.com/ • Upgrade Labs: https://upgradelabs.com Timestamps: 0:00 - Introduction 0:30 - Story #1: David Sinclair 2026 2:13 - Story #2: Google Drug Discovery 3:48 - Story #3: El Mencho Biohacking5:30 - Story #4: Measles Outbreak 6:51 - Story #5: Trump State of the Union 8:00 - Weekly Roundup 9:10 - Closing See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Cindy Eckert, entrepreneur, investor, and the central figure in the new Paramount+ documentary The Pink Pill: Sex, Drugs & Who Has Control. The documentary film examines the decade-long, uphill battle to get the first FDA-approved medication for female libido, Addyi, approved and brought to market. Directed by Aisling Chin-Yee, the film highlights the stark contrast between the fast-tracked approval of Viagra for men and the intense, often biased scrutiny faced by advocates of "female Viagra.” Eckert fought for 10 years to bring Addyi to market, facing regulatory roadblocks and public skepticism, ultimately revealing systemic gender bias in healthcare. Reality Life with Kate Casey What to Watch List: https://katecasey.substack.com Patreon: http://www.patreon.com/katecasey Twitter: https://twitter.com/katecasey Instagram: http://www.instagram.com/katecaseyca Tik Tok: https://www.tiktok.com/@itskatecasey?lang=en Facebook Group: https://www.facebook.com/groups/113157919338245 Amazon List: https://www.amazon.com/shop/katecasey Like it to Know It: https://www.shopltk.com/explore/katecaseySee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Watch every episode ad-free & uncensored on Patreon: https://patreon.com/dannyjones Brigham Buhler is a healthcare entrepreneur, founder and CEO of Ways2Well, and co-founder of ReviveRx Pharmacy. https://ways2well.com EPISODE LINKS https://www.instagram.com/brigham.buhler https://ways2well.com SPONSORS https://whiterabbitenergy.com/?ref=DJP - Use code DJP for 20% off FOLLOW DANNY JONES https://www.instagram.com/dannyjones https://twitter.com/jonesdanny OUTLINE 00:00 - Becoming the first drug rep for Cialis 04:47 - The primary care problem in America 07:20 - Why you should self-pay prescription drugs 12:10 - The dirty secret of anti-depressants 16:13 - The prescription drug incentive program 21:27 - 5 insurance companies cover 90% of Americans 23:31 - The Pharmacy Benefit Managers scam 28:48 - Think of health insurance like car insurance 31:27 - The #1 mistake we're making with our health 34:26 - The testosterone myth 38:51 - Why it costs $250M to bring a drug to market 44:32 - Why health insurance keeps you in the dark 45:31 - How we're fixing problems in healthcare 49:58 - How Brigham ended up on JRE 53:17 - Lobbying against peptides with the FDA 01:00:34 - Why "FDA-approved" products aren't always safe 01:06:08 - The "problem" with peptides 01:08:02 - The origin of the opioid crisis 01:11:48 - Pediatrician's vaccine schedules 01:17:55 - Changes in child vaccine requirements 01:21:41 - How fast medical knowledge becomes antiquated 01:25:21 - Why RFK backed down on vaccines 01:29:49 - Importance of flipping the food pyramid 01:33:44 - Combining IGF + GLP-1 drugs 01:36:50 - Jelly Roll's weight transformation 01:44:19 - Small wins = huge progress 01:47:44 - Brigham's efforts in the MAHA movement 01:54:15 - FDA's response to MAHA 02:00:01 - Protecting healthcare from future administrations 02:06:55 - American healthcare vs. other countries 02:08:44 - Food ingredients in US vs. Europe 02:15:15 - New stem cell treatments 02:17:06 - Why stem cells were banned in America 02:22:17 - New Japanese stem cell discovery 02:28:33 - Early anecdotal results from stem cell therapy 02:31:51 - We can create real-life X-Men 02:36:24 - Psychedelics & super soldiers 02:42:26 - The MINDS project (psychedelic problem-solving) Learn more about your ad choices. Visit podcastchoices.com/adchoices
CardioNerds (Dr. Jenna Skowronski [Heart Failure Council Chair], Dr. Shazli Khan, and Dr. Josh Longinow) are joined by renowned leaders in the field of AHFTC (Advanced Heart Failure and Transplant Cardiology) and mechanical circulatory support, Dr. Jeff Teuteberg and Dr. Mani Daneshmand to continue the discussion of advanced heart failure therapies by taking a deep dive into the world of durable LVADs (Left Ventricular Assist Devices). In this episode, we will review the history of ventricular assist devices, the basics of LVAD function, selection criteria for LVAD therapy, and surgical nuances of LVAD implantation. Audio Editing by CardioNerds intern, Joshua Khorsandi. Enjoy this Circulation 2022 Paths to Discovery article to learn about the CardioNerds story, mission, and values. CardioNerds Heart Success Series PageCardioNerds Episode PageCardioNerds AcademyCardionerds Healy Honor Roll CardioNerds Journal ClubSubscribe to The Heartbeat Newsletter!Check out CardioNerds SWAG!Become a CardioNerds Patron! Pearls There have been significant advances in the field of MCS/LVAD therapy since the first implanted LVAD in the 1960s, to the first FDA approved device in the early 2000's, to now the HM3 LVAD, with the most important change being a centrifugal flow/magnetically levitated design that led to minimized hemocompatibility-related adverse events (HRAE's) (MOMENTUM 3 trial comparing HM2 and HM3). The REMATCH trial in 2001 was a pivotal trial for LVAD therapy, demonstrating that in a population of patients with advanced HF (70% IV inotrope dependent), LVAD therapy significantly improved survival at both 1 and 2 years as compared to medical therapy alone. MOMENTUM 3 trial was a landmark trial for the HM3 device, showing that in a population of end stage HF patients (86% inotrope dependent, 32% INTERMACS 1-2, and 60% DT strategy), 5-year survival with HM3 was 58% and HM3 had lower HRAE's compared with HM2. There are both patient-specific factors and surgical considerations when it comes to candidacy for LVAD therapy. RV function prior to LVAD is a key determinant for success post-LVAD Many patients being considered for LVAD may not have robust RV function, however, predicting RV failure after LVAD is exceedingly difficult. In general, it doesn’t matter how bad the RV may look on imaging; we care more about the pre-LVAD hemodynamics (look at the PAPi and RA/wedge ratio). What happens in the OR may be the most important determinant of how the RV will do with the LVAD! Notes Notes drafted by Dr. Josh Longinow. 1. Historical background of heart pumps and LVADs LVAD Evolution FDA approval year 2001 2008 2012 2017 Pump HeartMate XVE HeartMate II Heartware HVAD HeartMate III Flow/Design Features Pulsatile Technology Continuous flow Axial design Continuous flow Centrifugal design Continuous flow Full MagLev + Centrifugal design The 1960's ushered in the first ‘LVADs', when the first air-powered ‘LVAD' was implanted. It kept the patient alive for four days before the patient expired. The first generation of LVADs were pulsatile pumps The first nationally recognized, FDA approved LVAD was the HeartMate XVE (late 1990s to early 2000s, REMATCH trial). The XVE pump used compressed air (pneumatically driven) to power the pump. Prior to the XVE, OHT was the standard of care for patients with advanced, end-stage heart failure. The second and third generations of LVADs were non-pulsatile, continuous flow devices and included the HVAD, HM2, and HM3 devices. MOMENTUM 3 was a landmark trial for the HM3 device, showing that in a population of sick patients with end stage HF (86% inotrope dependent, 32% INTERMACS 1-2, and 60% DT strategy), 5-year survival with HM3 was 58% and HM3 had lower HRAE's compared with HM2. The only pump that is currently FDA approved for implant is the HM3, although other pumps are in clinical trials (BrioVAD system, INNOVATE Trial). 2. What are LVADs, and how do they work? In simplest terms, the LVAD is a heart pump comprised of several key mechanistic components: Inflow cannula Mechanical pump Outflow cannula Driveline Controller/Power source The HM3 differs from its predecessors (HM2 and HVAD) in several key ways; HM3 is placed intrapericardial whereas the HM2 was placed pre-peritoneal. Perhaps most importantly, the HM3 is a fully magnetically levitated, centrifugal flow pump, whereas the HM2 is an axial flow device. Axial flow pumps are not magnetically levitated, leading to more friction produced between the ruby bearing's contact with the pump rotors, and higher rates of hemocompatibility related adverse events (HRAEs, i.e. pump thrombosis) and the HM2 was ultimately discontinued in favor of the HM3 (MOMENTUM 3 trial). 3. What do the terms ‘Destination Therapy' (DT) or ‘Bridge to Transplant' (BTT) mean when it comes to LVADs? When LVADs first came on the stage, EVERYONE was a BTT; these early pumps weren't designed for long term use (I.e. REMATCH Trial, Heartmate XVE) Destination therapy means the LVAD was placed in leu of transplant because there are contraindications to transplant REMATCH trial brought about the concept of “Destination therapy”, comparing outcomes in patients (with contraindications for transplant) who received an LVAD vs optimal medical therapy Bridge to transplant means we are placing the LVAD in a patient who may not be a transplant candidate at this moment in time (is too sick, or conversely, not sick enough), but may be down the line Bridge to recovery is another term used when the LVAD is being placed for a patient we think may have a recoverable cardiomyopathy 4. What are some factors we should consider when assessing a patient’s candidacy for LVAD, in general, and from a surgical perspective? Patient factors Older age might push us towards thinking LVAD rather than transplant In general, age > 70 is the cutoff for transplant, but this is not a hard cut off and varies institution to institution In general, think about things that help predict recovery after a major surgery; Frailty and Nutritional status are important, we try to optimize these prior to LVAD implant Right ventricular function remains the Achilles heel of LV support We know that needing temporary RV support post LVAD puts you on a different survival curve than patients who don’t need RVAD support Studies have not been able to successfully predict who will develop RV failure after LVAD implantation What happens in the time between when the patient goes to the OR and when they get back to the ICU is an important determinant who might develop RV failure post LVAD Surgical techniques such as implanting the HM3 in the intra-thoracic cavity, rather than intra-pericardial may help maintain LV/RV geometry to help optimize the RV post LVAD Surgical considerations for LVAD candidacy Small, hypertrophied LV: HM3 inflow cannula is small, but small hypertrophied ventricles tend towards chamber collapse during systole causing suction, needing to run slower with lower flow rates Chest size/diameter: pumps have gotten so small now, that for adults, these have become less of a consideration BMI: low BMI used to be more of a concern with the older pumps due to where they were placed, and the relative size of the pump itself, not so much now with the smaller HM 3 pumps Calcified LV apex: would increase risk of stroke, bleeding Driveline tunneling becomes a concern in the super obese population, higher risk for driveline infections (might tunnel these driveline's shorter, and to a less fatty region of the abdomen, could even tunnel out the thoracic cavity in the super obese to limit skin motion) 5. Is there a role for MCS (i.e. temporary LVAD such as Impella) in pre-habilitation of patients prior to LVAD surgery? The theory of being able to improve systemic perfusion, decongest the organs, and make the patient feel better prior to surgery makes sense, but becomes problematic due to the lack of a hard end point/time for prehabilitation which might risk delays in surgery More likely that it can lead to delay in the surgery, with less-than-optimal benefit; you don't want to prolong the wait for surgery and increase the risk for complications prior to surgery An Impella 5.5 is currently FDA approved for 2 weeks of support, not 2 months so timing is important to keep in mind It’s unlikely that you will take a patient and convert them from a malnourished, cachectic person in 2 weeks’ time 6. Is there a role for LVAD therapy in the younger patient population? Should we be thinking of LVAD up front for these patients, with the goal of transplanting down the line? Recovery may be more likely in certain populations, particularly younger females with smaller LV's; in those populations, perhaps bridge to recovery should be the focus, optimizing them on GDMT etc. The replacement of transplant, with MCS (LVAD) in young patients has become a topic of discussion, because these pumps have become better and better, with the thinking that an LVAD could bridge a patient for 10 years or so, and they could get a transplant later It is still a big unknown, but several concerns exist Patients who get LVADs might end up with complications that become contraindication to transplant down the line (stroke, sensitization etc) Patients and providers are more hesitant because of the more recent iteration for the UNOS criteria for OHT listing which no longer gives patients with an uncomplicated LVAD higher priority, and therefore they could end up waiting a longer time for a heart after undergoing LVAD References Rose EA, Gelijns AC, Moskowitz AJ, et al. Long-term use of a left ventricular assist device for end-stage heart failure. N Engl J Med. 2001;345(20):1435-1443. doi:10.1056/NEJMoa012175 Mehra MR, Uriel N, Naka Y, et al. A Fully Magnetically Levitated Left Ventricular Assist Device – Final Report. N Engl J Med. 2019;380(17):1618-1627. doi:10.1056/NEJMoa1900486 Mancini D, Colombo PC. Left Ventricular Assist Devices: A Rapidly Evolving Alternative to Transplant. J Am Coll Cardiol. 2015;65(23):2542-2555. doi:10.1016/j.jacc.2015.04.039 Mehra MR, Goldstein DJ, Cleveland JC, et al. Five-Year Outcomes in Patients With Fully Magnetically Levitated vs Axial-Flow Left Ventricular Assist Devices in the MOMENTUM 3 Randomized Trial. JAMA. 2022;328(12):1233-1242. doi:10.1001/jama.2022.16197 Rose EA, Moskowitz AJ, Packer M, et al. The REMATCH trial: rationale, design, and end points. Randomized Evaluation of Mechanical Assistance for the Treatment of Congestive Heart Failure. Ann Thorac Surg. 1999;67(3):723-730. doi:10.1016/s0003-4975(99)00042-9 Kittleson MM, Shah P, Lala A, et al. INTERMACS profiles and outcomes of ambulatory advanced heart failure patients: A report from the REVIVAL Registry. J Heart Lung Transplant. 2020;39(1):16-26. doi:10.1016/j.healun.2019.08.017 Mehra MR, Netuka I, Uriel N, et al. Aspirin and Hemocompatibility Events With a Left Ventricular Assist Device in Advanced Heart Failure: The ARIES-HM3 Randomized Clinical Trial. JAMA. 2023;330(22):2171-2181. doi:10.1001/jama.2023.23204 Mehra MR, Nayak A, Morris AA, et al. Prediction of Survival After Implantation of a Fully Magnetically Levitated Left Ventricular Assist Device. JACC Heart Fail. 2022;10(12):948-959. doi:10.1016/j.jchf.2022.08.002 Bhardwaj A, Salas de Armas IA, Bergeron A, et al. Prehabilitation Maximizing Functional Mobility in Patients With Cardiogenic Shock Supported on Axillary Impella. ASAIO J. 2024;70(8):661-666. doi:10.1097/MAT.0000000000002170
This 'Media Buzz Meter' first aired on February 19th, 2026… Howie Kurtz on Former Prince Andrew being arrested on allegations of sharing UK trade secrets with Jeffrey Epstein, the partial government shutdown impacting FEMA's disaster recovery efforts, and the FDA's decision to review Moderna's application for an mRNA-based flu vaccine. Learn more about your ad choices. Visit podcastchoices.com/adchoices
What if the reason you’re not healing isn’t that you need another diagnosis? 0:08 It’s that your cells aren’t receiving the right signals. Because the body doesn’t run on diagnosis, it runs on 0:16 communication. And peptides are one of the most powerful, most misunderstood 0:21 tools we have for cellular signaling, immune balance, tissue repair, gut 0:27 lining support, metabolic control, brain signaling, sleep cycles, and even sexual 0:35 wellness. Today, I’m going to do what most people won’t. Define peptides in 0:41 plain English for you. break them into categories by what they’re best at and 0:47 tell you which ones are FDA approved on the list and which ones are commonly 0:53 used off label or investigational with the evidence that actually says these 1:00 work. This is going to be a powerful episode and if you’ve ever felt like you’re hearing hype without clarity, 1:07 this one’s for you. So, as usual, grab your cup of coffee or tea and settle in 1:13 as we talk about peptides that can fit into your healing journey. We’re going 1:19 to have a short word from our sponsor. You know, we got to do that. That’s how we stay on the air here. So, we will be 1:26 right back after this. Did you know sweating can literally heal your cells? 1:32I nfrared saunas don’t just relax you. They detox your body, balance hormones, 1:37 and boost mitochondrial energy. I’m obsessed with my health tech sauna. And 1:42 right now, you can save $500 with my code at healthtechalth.com/drmuthqen25. 1:54 All right, here we go, guys. I am excited to dive into peptides with you. 2:00 So understanding peptides is foundational, right? And I’ve been 2:06 studying peptides now for about nine years. Um, and I find that they are 2:13 incredible. Um, so I want to break down for you what peptides actually are, what 2:19 they do, and some of the top peptides that are available today, and how they 2:25 can be utilized. Because I think it’s really important. And I think it’s it’s there’s a lot of confusion out there about what these things actually are and 2:32 are they safe? Are they not? When do we use them? What’s the science behind them? So, we’re going to dive in and 2:38 we’re going to talk about all things peptides. So, let’s get ready here. Here we go. So, peptides are short chains of 2:45 amino acids and they typically range anywhere from 2 to 50 amino acids and 2:51 they’re linked by peptide bonds. So think of them as the superglue that holds the amino acids together. They sit 2:58 between the amino acids and they are full proteins in terms of their size and 3:04 their complex structure. And what makes peptides particularly interesting in 3:10 medicine is their role as signaling molecules. They’re essentially the 3:15 body’s text messages carrying specific instructions to cells and tissues. And 3:21 unlike our proteins which often serve as structural roles or act as enzymes, 3:28 peptides typically function as hormones, neurotransmitters and growth factors and 3:33 they bind to specific receptors on the cell’s surfaces or within the cells and 3:39 they trigger this effect. It’s like a cascade effect of a biochemical reaction 3:45 that ultimately changes the cellular behavior. So basically, it’s changing 3:50 the way the body’s cell structure acts. And this is why peptides can be so 3:56 incredibly powerful and therapeutic when you introduce the right peptide signal. 4:02 Now, you could theoretically redirect cellular processes toward healing, 4:07 towards metabolism, immune balance, tissue repair. Any of those things can 4:14 be manipulated to do a certain thing once we add the peptide. The challenge 4:19 in peptide medicine though lies in distinguishing between those peptides that have been rigorously studied, 4:26 proven safe and effective and approved by regulatory bodies like the FDA versus 4:31 those that exist in what we call the gray zone of a promising clinical data. 4:36 But they really lack human validation so far. And this distinction is critical because the presence of a plausible 4:43 mechanism does not guarantee safety or efficacy in living humans. So, this is 4:50 really important and we’re going to dive in and look at some of the research on all of these different peptides that are 4:56 available and I’m excited to say there’s some amazing peptides being studied right now that unfortunately are not 5:01 available. But I can’t wait to see them hit the market for us because it is going to be a gamecher as far as health 5:09 and longevity. So there is a quality control issue and there is a hidden 5:14 variable in peptide medicine with this and it’s one of the most underappreciated aspects of peptide 5:21 therapy particularly for non-FDA approved peptides. It’s quality control. 5:26 When we discuss pharmaceutical medicines, we take for granted that the pill contains what the label says. Not 5:32 always true depending on where it comes from. You guys, if you’ve heard my episodes before talk about how many of our medications are made in China and 5:41 have been contaminated with other things, you will realize that that is not always true. So, just because it has 5:48 the FDA stamp of approval on the medication, it still does not necessarily mean it’s safe and we still 5:54 need to do our homework on it. So, sorry for digressing on you guys, but you know, when we get a medication, we we 6:00 think that what the amount says is what is there, doesn’t have contaminants, it’s manufactured with good 6:06 manufacturing practices. You’ll see that listed as GMP on the bottle, and it’s been stored properly, it’s been 6:12 maintained stable, and with research peptides and compounded formulations, 6:17 none of this can be assumed. So, I will share a story with you. There was a gentleman that was purchasing these 6:24 peptides online from a research facility and um did not know that they were 6:30 coming from China and he was ordering a particular growth hormone peptide and 6:35 after a little while he had he had done fine for the few first few bottles. After a little while he started having 6:42 some complications. He started getting really irritable and angry and ragy and 6:47 he didn’t quite know what was going on. And so he decided to go get some testing done. He had some blood testing done and 6:53 his testosterone level was over 5,000. So for those of you who know what testosterone level should be for a guy, 7:00 they really shouldn’t be any higher than about 1,00200 would be absolute max that we’d want to see. Now he was taking 7:06 testosterone but not to that degree. And prior to adding this peptide, his 7:12 testosterone was very stable. What they ended up finding out was the peptide that he was getting, whoever was 7:18 manufacturing it added testosterone to the peptide. They felt like if if it had growth hormone, that was great, but if 7:25 it had growth hormone and tes testosterone, all the better. And he didn’t know that. And this is the 7:31 problem that we can have with peptides if you don’t source them properly. if you’re not working with somebody that 7:37 knows how to source them and can prove that they are what they say they are. Um, I’m sure there’s a whole bunch of 7:42 studies out there too of people getting these peptides and paying hundreds of thousands of dollars for them over their 7:48 lifetime and finding out they were nothing more than just sterile water. So, you really do need to be careful 7:53 with your quality control. Now, this kind of leads us right into the next topic that we’re going to talk about and that’s the manufacturing question, 8:00 right? The FDA approved peptides are manufactured in facilities subject to 8:05 the FDA inspection rules following our GMP regulations and these facilities 8:11 must validate their manufacturing process, demonstrate consistency batch to batch, test for purity and potency. 8:18 They need to test for bacterial endotoxins and sterility and they need to maintain detailed records. So, when a 8:25 pharmaceutical company submits a drug application, the FDA inspects the manufacturing facility as part of the 8:32 approval process. If you’re getting peptides from a different country, none of that is happening. And there are some 8:38 ways for us to determine if that is what you’re getting. Typically, the rule of thumb is if your peptides are coming 8:44 with a different colored top, every one of them has a different colored top. Those are typically being sourced out of 8:49 China. I wouldn’t say that’s 100% but that’s kind of the rule of thumb that people follow. So compoundingies these 8:56 are thearmacies that make our bio identical hormones. They can make medications in any dose or strength or 9:02 route. There are thousands of them in every not that not in every state but 9:08 there are thousands of them around the country right now. So these compoundingies are registered as 503A 9:15 facilities. They do traditional compounding for individual prescriptions, right? Like they can make 9:20 thyroid, they can make LDN, they can make estrogen. You can also have a 503b 9:27 facility, which is an outsourcing facility. And these companies produce larger batches of products. They’re they 9:34 have some oversight, but they’re less stringent than for FDA approved 9:40 manufacturers. And state boards of pharmacy regulate a 503A pharmacy. And 9:45 the FDA can inspect the 503b facility, but doesn’t preapprove any of their 9:52 compounding products. So, they can inspect it, but they don’t approve them. So, research chemicals and these 9:58 suppliers operate essentially with no oversight. They explicitly market products for research use only, not for 10:06 human consumption to avoid FDA regulation. If they put that on their 10:12 product, they don’t have to comply to what the FDA is saying. And there is no required manufacturing strategies or 10:19 standards, no required testing, no required sterility assurance, and no enforcement mechanisms if products are 10:26 mislabeled or contaminated. So basically, they don’t have the liability, but that doesn’t mean that 10:31 all of them are badies or bad suppliers. It just means they don’t have to comply 10:37 to the FDA rules. Now, there are many of these companies that I’ve seen and I’ve talked to that do do a lot of this. They 10:44 do test their product for sterility. They do test their product to make sure it is what it says it is. They don’t 10:51 have to, but they do. So, if you’re going to decide to use a company that 10:56 has research only, not for human consumption, at least ask for their 11:02 proof of testing so that you know that the product you’re getting is what it says it is and that it’s clean. Because 11:08 this is where we run into the problem is in purity. So in purity peptide 11:13 synthesis can produce not just the targeted peptide but also related 11:19 peptides with deletions, substitutions, truncations or truncations of amino 11:25 acids. Sorry. And this high performance liquid we call it uh chromatography can 11:30 separate these related impurities and quality and quantify the actual target 11:35 of the peptide content. So a certificate of analysis is what you want to ask these companies for. This shows the HPLC 11:44 the testing mechanism with greater than 95% or ideally 98% purity which 11:51 indicates a higher quality product. So this certificate of analysis can be fabricated may not represent the 11:57 specific batch being sold. It happens. We need to know not everybody is honest. Not everybody, you know, does what they 12:03 say and it does what’s right. But at least you at least they’re giving you something and you have some security. 12:10 and then choose a company that was referred to by someone else that has done some homework as well. In in 12:16 commercial research, there’s independent testing and they research peptides and this has been really shocking 12:23 variability that they’ve seen. Some products contain 50% or less of the 12:29 claimed peptide and some contained primarily degradation of the product or manufacturing impurities and some 12:36 contained bacterial endotoxins at levels that could cause fever and systemic 12:42 inflammation if it was truly injected. And I would also worry with some of those problems, you know, depending on 12:48 what impurity or bacterial endotoxin was there. If you’re using a product to boost your immune system and your immune 12:54 system is already compromised, these bacterial endotoxins can actually make you sicker instead of what you want it 13:02 to do, which is making you better. So, sterility is always an issue with anything that is manufactured, 13:08 especially things that we’re doing as an injection. Peptides are intended for injection. They must be sterile. They 13:16 must be kept safe. And pharmaceutical manufacturers conduct this sterility testing on every batch. 13:22 Compoundingarmacies should conduct sterility testing particularly for high-risisk compounded 13:28 sterile preparations and research chemical suppliers may or may not conduct any testing. So injecting 13:35 non-sterile material can cause local infections, abscesses at the injection 13:41 site and or if the bacteria enters the bloodstream could potentially be 13:46 life-threatening and you could have sepsis. Now, excuse me. We saw this 13:52 happen in a compounding pharmacy uh gosh, it’s probably been 10 years ago 13:57 now, I think. um they unfortunately had a strep uh contamination in their 14:03 product and they weren’t testing it. It was a large compounding pharmacy out of Florida and they were making products 14:08 that were being injected into the joints and um these people got very very sick 14:14 and some of them died and um some of them got very very injured by this uh 14:21 complication that happened. So it’s not like this doesn’t happen. It does, but it doesn’t happen often. And that’s what 14:28 we have to know about. And so, when we’re talking with you guys about storage and stability, it’s really 14:34 important to make sure you maintain your peptides well. So, many peptides are unstable at room temperature. They 14:41 require refrigeration or freezing. We tell everyone to make sure you’re refrigerating your peptides. That way, 14:48 there’s no question about it. when it stays cold um it prevents or slows down 14:54 the process of uh bacteria growing in it. So some of these peptides actually 14:59 degrade very rapidly in the solution and they must be reconstituted immediately before use and reconstitution of the 15:07 peptides really has limited stability often just days to weeks not months. So 15:13 improper storage, temperature, um changes during shipping or prolonged 15:19 storage of a reconstituted product can lead to degradation into inactivity or 15:25 potentially even a harmful breakdown of the product itself. So if you have a product that’s been sitting in your 15:30 refrigerator for a month or two months or 3 months or 6 months, just throw it away. It’s not going to be any good. 15:37 you’re not going to actually get the peptide and the uh potency that you’re looking for anyway out of it and the 15:44 potential of you introducing an endotoxin, a bacterial endotoxin is quite high at that point. So you just 15:50 really don’t want to take the risk, excuse me. So what practitioners, what 15:56 should we do and what should patients do? Well, for any peptide therapy, we 16:03 want to source our verification. know where the peptide product comes from. Is 16:08 it an FDA approved product? Is it a 503b compounding? A research chemical 16:14 supplier? Is there a certificate of analysis? Request and review this COA. 16:20 And you want it to show purity greater than 95% but ideally greater than 98%. 16:27 You want that identity be identity to be confirmed by mass spectromedy. Uh 16:33 sterility testing should be done. Bacterial endotoxin testing should be done. Batch number matching of the 16:39 product that you received should be done. Proper storage. You want to know that this has been refrigerated or 16:46 frozen as directed once it’s been mixed. Look at the expiration dates for reconstituting your peptides. Track that 16:53 reconstitution date and discarded accordingly like we just talked about. Monitor for your adverse effects. Even 17:01 with the perfect quality control, monitoring for adverse effects is essential with questionable quality and 17:08 vigilance is really critical here. I know it’s frustrating for a lot of patients when they have to get several 17:15 bottles and they only last a week or two. right here, you guys. This is why 17:21 they only last a short period of time because once they’re mixed, they start 17:26 to degrade and they won’t be good and you won’t get the benefit from it. So, 17:31 it’s really important with these research peptides specifically, practitioners should recognize that all 17:38 recommending products without quality assurance violates the fundamental medical principle of first do no harm. 17:45 If a patient is determined to use research peptides despite counseling, providing guidance on quality 17:52 verification, requesting those COAs, using pharmaceutical grade sources when available, proper testing, this all 17:59 reduces harm, but doesn’t constitute necessarily that recommendation. Now, 18:06 that being said, today it’s very difficult to find peptides by the compoundingies because of what the FDA 18:13 has done. So most of the peptides that are available to us have been labeled 18:18 not for human consumption, not because they’re not good products, but because 18:25 of what the FDA did. And this is how these companies have been able to 18:31 continue to provide peptides to the medical community. And if you know you 18:36 have a good company, then you’re, you know, you’re still taking the risk, right? But at the end of the day, the 18:42 reason they’re doing that is to protect themselves from the FDA, from liability. Um, so just kind of know that there is 18:50 some talk in the community with um Bobby Kennedy that this is going to change and 18:55 they are going to bring peptides back to the compounding pharmacies. Now, we don’t know which ones they’re going to 19:01 bring back. Uh, will it be all of them? Will it just be some of them? What’s going to happen here? Um, is it going to 19:07 go to the pharmaceutical companies like our GLP1s did? We don’t know what that’s going to look like quite yet. Um, but it 19:14 is coming and that is positive news. So, let’s talk now about FDA approved 19:21 peptide medications. So, this is the metabolic revolution, right? GLP1 19:28 and our dual increeting agonists. This is an exciting time. GLP-1s are amazing. 19:35 Um, a lot of people are skeptical, a lot of people love them, a lot of people hate them. Whichever side of the fence 19:42 that you’re on, I understand. But I want to talk about the science of it today 19:48 and what it actually means for people. So, the story of GLP1 glucagon like 19:54 peptide one represents one of the most significant advances in metabolic 19:59 medicine in the past several decades. GLP-1 is an accretin hormone. It’s 20:05 gutder derived peptide that potentiates insulin secretion in response to food 20:11 intake. And the body naturally produces GLP-1 in the intestinal L cells, but it 20:17 rapidly degraded by the enzyme DPP4 giving it a halflife of only about 2 20:24 minutes. So this rapid breakdown made in therapeutically impractical until 20:31 research was developed and modified the analoges that resist the enzyme degradation. So for those people who 20:39 never feel full when they’re eating, never feel satisfied when they’re done, this is because their body is either not 20:46 producing enough GLP1 or it’s not getting the signal right. And this is a 20:51 leptin issue. This is an insulin issue. It’s a GLP-1 issue. It’s a complicated 20:56 issue. This is not anything that the person is doing wrong. It’s what is happening to their body. And so GLP1s 21:03 have really revolutionized this. So one particular GLP-1 that we have is 21:09 semiglutide. And this GLP-1 agonist is what changed everything in the world of 21:16 metabolic medicine. Semiglutide is marketed as ompic for type 2 diabetes 21:23 and it’s marketed as WGOI for chronic weight management. It is a modified 21:29 GLP-1 analog with 95 or sorry 94% amino acid sequence uh homology to human 21:37 GLP-1. So it means that it’s it’s just like our own GLP-1 that we make. This 21:42 modification includes specific amino acid substitutions and the addition of C18 21:50 a fatty acid chain which allows the peptide to bind to albumin. Now this 21:56 albumin binding dramatically extends the half-life to approximately one week 22:01 enabling one weekly dosing which is a major advantage over the earlier GLP-1 22:07 agonists that require daily or twice daily injections. The mechanism by which 22:13 semiglutide works is multiaceted. At the pancreatin level, it binds to GLP-1 22:20 receptors on the pancreatic beta cells enhancing glucose depending sorry 22:27 enhancing glucose dependent insulin secretion. This glucose dependency is 22:33 crucial. It means the peptide only stimulates insulin release when blood glucose is elevated. This dramatically 22:41 reduces the hypoglycemic risk compared to insulin or even uh sulfuras. 22:47 Simultaneously semiglutide suppresses glucagon secretion from pancreatic alpha 22:53 cells further improving glycemic control. This is really amazing because 23:00 over the years when we’ve used insulin, which is also a peptide by the way, you 23:05 had to dose it just right because if you didn’t, you would produce so much insulin that it would crash the blood 23:12 sugar and then somebody would have too low of a blood sugar. They’d be hypoglycemic and they’d have to eat more 23:18 sugar and then they’d have to modify the insulin again and the person would be going up and down, up and down, up and 23:24 down all day long. And that created a lot of problems for people and so this 23:30 helps to stabilize that so it is not such an intense change. Now in the GI 23:36 tract semiglutide delays the gastric emptying particularly pronounced during 23:41 the initial weeks of therapy. This slowing of the gastric emptying contributes to the sensation of being 23:48 full and early satiety that patients often describe. However, this effect 23:54 tends to attend to weight over time as the body adapts through the appetite 24:00 suppressing effects generally persist through central mechanisms. So, when we 24:05 talk about what is actually happening, we’re slowing that digestive process down. That’s why people aren’t so 24:11 hungry. It’s why they’re not eating so much. This is why people can develop constipation with these products because 24:17 it’s slowing the body’s digestive tract down. Now some people will call this 24:22 gastroparesis. Um gastroparesis is actually different. 24:28 It is when we lose control over what’s happening in the in the colon like the 24:34 nerves and things like that just stop working. I have never seen that with the GLP1s that we prescribe in micro doing. 24:42 um it’s been documented. It can happen, but again it a lot of it is dosing and a 24:48 lot of it is staying on top of your client and what’s happening and what’s going on and what you’re doing and making sure that they do have good 24:54 motility still. So a lot of these things can be mitigated if you have problems 24:59 with them. Now one of the most profound effects of semiglutide occur in the 25:05 central nervous system. GLP-1 receptors are widely distributed in the brain 25:10 particularly in the hypothalamus and the brain stem area where we are involved in 25:15 appetite regulation. So when when wilding and colleagues published their 25:20 landmark step one trial in the New England Journal of Medicine in 2021, 25:25 they demonstrated that participants receiving 2.4 4 milligrams of semiglutide weekly achieved an average 25:32 weight loss of 14.9% of their body weight over 68 weeks. Now, I want you 25:39 guys to really understand this. We’re talking roughly 15% body weight loss 25:45 over a year, longer than a year. 52 weeks is a year, right? This is 68 25:50 weeks. So, it took longer for them to lose. We’re not talking about giving 25:55 somebody a dose to lose 15% of their body mass in a month or two. That that 26:01 is not healthy for any of us. That is not what we’re talking about doing here. Now, they compared this to placebo and 26:08 the placebo was only 2.4%. So, that is a significant difference. 26:14 And even beyond the numbers, patients reported something very qualitatively different, a reduction in what’s now 26:21 called food noise. Everybody knows what food noise is. We’ve talked about this long before GLP1. It’s that craving. 26:28 It’s that part of your brain that just keeps thinking about I want to eat something. You know, that was actually 26:34 reduced and they didn’t expect to see that happen. Now, this refers to the constant mental preoccupation with food, 26:42 the intrusive thoughts about eating, the difficulty in feeling satisfied. Semi-glutide appears to appears to 26:49 modulate reward pathways in the misolyic system reducing hedonic eating and food 26:57 cravings. Now there are also great cardiovascular effects of semiglutide 27:02 that extend beyond weight loss. Uh the sustained six and select trials 27:07 demonstrated significant reductions in major adverse cardiovascular events uh 27:14 mace in high-risisk populations. The select trial published in 2023 showed 27:20 that semiglutide reduced cardiovascular death, non-fatal myioardial inffection 27:25 and non-fatal stroke by 20% in adults with overweight or obesity and 27:31 established cardiovascular disease but without diabetes. So this suggests that 27:37 mechanisms beyond glucose control and weight loss possibly including 27:42 anti-inflammatory effects, improvements in endothelial function and favorable 27:47 changes to lipid profiles. Now I will tell you the clients that I work with that are on GLP1, 27:53 they will tell you that their inflammation has been significantly reduced. We are also seeing really 28:00 amazing results in lipid profiles. um part of its weight loss, but there is a 28:06 component to this that is lowering the triglyceride levels because it’s related to sugar and how the body’s processing 28:11 it. And we’re seeing better profiles, less need for statins as a result of 28:17 that. If if you want to listen to my episode on statins, I have one on that. Uh they are not my favorite medication. 28:24 I think it’s overprescribed and overused um and not really affecting or 28:29 addressing the problem. So these things can really be helpful. There’s also some 28:34 uh ramblings going on with GLP-1s saying that they may be able to help with 28:40 addiction in the future because of where they’re finding it affecting the brain and how it affects the food noise and 28:47 the cravings that we have for food and the addiction for food. Could it potentially help with other addictions 28:53 down the road? We’ll have to wait and see on that one. So semiglutide’s FDA prescribing information also includes a 29:00 box uh boxed warning about thyroid sea cell tumors. So in rodent studies 29:06 semiglutide caused dose dependent and treatment duration dependent sea cell 29:12 tumors at clinically relevant exposures. So while it’s unknown whether or not 29:17 semiglutide causes uh thyroid cancer tumors in humans and the rodent thyroid biology 29:26 differs significantly from humans, the drug is contraindicated in patients with a personal or family history of 29:33 medillary thyroid carcinoma or in patients with multiple endocrine neopl neoplasia syndrome type two. it is 29:42 uh contraindicated for safety effects with that. Um I have seen endocrinologists okay GLP1s to be used 29:50 in patients who’ve had other forms of thyroid cancer just not the meillary 29:55 thyroid cancer. So there is possibility there. Now the most common side effects 30:00 are gastrointestinal. It’s nausea affects about 20 to 44% of patients 30:06 depending on the formulation with diarrhea, vomiting, constipation, abdominal pain, and also frequently 30:13 reported in clinical trials. I see this in my clinic, too, especially dose dependent. Um, and it happens early on 30:20 when you’re first starting the medication, but seems to settle out over time. The one that I would add to this 30:26 that I don’t think they have on here is an increase in acid reflux. We also see that quite often uh especially in people 30:33 who suffer with acid reflux to begin with. Now these effects are typically most 30:40 pronounced during the escalation and they like I said often improve over time 30:45 but more serious but less common adverse effects include acute pancreatitis. 30:51 The medication needs to be discontinued immediately if this is confirmed. You can see some diabetic retinopathy 30:57 complications in patients with pre-existing retinopathy and acute kidney injury. Um, this usually happens 31:05 secondarily to dehydration from the GI effects. There are some gallbladder disease um that can occur and people who 31:13 have a sensitive gallbladder will describe uh discomfort with that. I’ve 31:18 even seen some people who’ve had their gallbladder out on GLP1s at the higher doses complain of similar pain that they 31:25 used to have when their gallbladder was in. So, really important to just kind of monitor these symptoms and work closely 31:32 with somebody that understands them and can be on top of them quite quickly if this happens. Excuse me. From an 31:39 integrative medicine perspective, semiglutide really represents a powerful tool, but it’s not a standalone 31:46 solution. Remember, the medication addresses one aspect of the metabolic dysfunction, the signaling systems 31:53 controlling appetite and glucose homeostasis, but it doesn’t address the root cause that led to the metabolic 32:00 disease in the first place. Patients who rely solely on the medication without addressing the ultrarocessed food 32:07 consumption, the ccadian disruptions, the chronic stress, the sleep apnea, or 32:12 underlying hormonal imbalances often experience weight regain when the medication is discontinued. 32:20 The drug is also not a substitute for addressing the emotional and psychological drivers of eating 32:26 behavior, including the unresolved trauma that may manifest as emotional eating. I think this is really important 32:33 because we don’t address the trauma issue enough with clients and we need to 32:38 be looking at that. There is a huge trauma effect out there these days that is I don’t want to say leading to or 32:45 causing but it is definitely contributing to chronic illness and it’s not being talked about enough. So we 32:52 really need to be talking about this and addressing this trauma aspect. Now the next GLP that one that I want to talk 32:59 about is trespathide. This is a dual agonist. It takes center stage. It is my 33:05 favorite GLP one. Trisepatide is marketed as Mangjaro for type 2 diabetes 33:11 and Zepbound for chronic weight management and it represents the next 33:16 evolution in increantbased therapy. This is a dual agonist a 39 amino acid 33:23 synthetic peptide structurally based on the human glucose dependent insulin tropic peptide so GIP sequence but 33:31 modified to activate both the GIP receptors and the GLP1 receptors. So the 33:37 addition of the GI GIP agonism to the GLP1 agonism appears to create this 33:46 synergistic effect that goes beyond simply adding the two mechanisms together. So the GIP like GLP-1 is an 33:55 increant hormone secreted by what is called the K cells in response to nutrient intake. It enhances glucose 34:02 dependent insulin secretion but it also effects on atapost tissue metabolism 34:09 potentially improving the insulin sensitivity in fat cells and influencing 34:14 how the body stores and metabolizes fat. So some research suggests that GIP may 34:20 also have effects on energy expenditure though this remains an area of 34:26 investigation. So basically what we’re saying is this drug may actually help 34:32 people who are insulin resistant or insulin sensitive, not just somebody who 34:38 has problems with glucose control. So, this is super exciting because it opens 34:43 up the door for all of these people for decades that we’ve been trying to manage with insulin resistance and trying to 34:50 prevent diabetes and honestly most of the time have been unsuccessful 34:56 unless you can keep your diet at 50 grams of carbs or less a day, which is extremely difficult. Um, and take some 35:04 supplements that may or may not work and or take some metformin that may or may not help. this drug actually really 35:11opens that up and helps in that capacity. So there was a clinical trial 35:17 called the surmount clinical trial which demonstrated that trespathide produces 35:22 even more substantial weight loss than semiglutide. In the surerount one trial published by uh J tree I might have said 35:31 that wrong. I apologize if I slaughtered your name and colleagues in the New York England Journal of Medicine in 2022. 35:38 Participants receiving the highest dose of trespide, which is 15 milligrams, achieved an average weight loss of 20.9% 35:47 of their body weight over 72 weeks, compared to 3.1% with placebo. This 35:54 level of weight loss approaches what’s typically only seen in beriatric surgery. So, this is amazing because if 36:02 this medication works and we don’t have to do beriatric surgery, stomach stapling basically, um, oh my gosh, it’s 36:11 amazing. There are so many complications and risks that go with stomach stapling and the different procedures that they 36:17 do these days. People don’t absorb their nutrients properly. They have to do liquid nutrients. It’s very complicated. 36:24 It’s very challenging. Many of these people gain their weight back. Um, and 36:30 this procedure is not fun to go through. So, if we could change that and change 36:35 the lives of people who’ve really been struggling, it is amazing. And I will tell you that I have seen this work. I 36:42 have seen people lose 100 150 pounds on these medications over a year or two 36:50 period of time. It is definitely slower than beriatric surgery on some standpoints, but that is okay. You don’t 36:56 want that rapid weight loss. It’s not good for you. It’s not healthy for you. It doesn’t look well. You know, we want 37:03 to do this safely and effectively in the best way that we can possibly do that for you. Now, the adverse effect profile 37:10 is similar to semiglutide. It’s dominated by gastrointestinal effects. 37:15 Nausea, diarrhea, decreased appetite, vomiting, constipation. These were all commonly reported in the surmount 37:22 trials. And like semiglutide, tricepide carries a blackbox warning regarding the 37:27 thyroid sea cell tumors based on the rodent data and it shares the same contra indications in patients with a 37:34 family history of thyroid cancer and men too. So the mechanism behind why 37:40 tepatide often produces more substantial weight loss than GLP-1. The agonism 37:45 alone remains under investigation, but it may relate to the complimentary effects on the different aspects of 37:51 energy homeostasis or to GIP’s effects on atapost tissue and potentially on 37:58 central central nervous system pathways that GLP1 alone doesn’t fully address. 38:03 Now patients often report even more profound reductions in food noise with tricepide compared to GLP1 and uh sorry 38:12 GLP1 the agonists through this is anecdotal and hasn’t been regularly 38:17 quantified in quality studies. So I’ve done both uh personally and in my 38:22 practice. I really like trespide better than semiglutide. For me I had too many side effects with semiglutide. uh I had 38:30 less side effects with trespathide. I also plateaued on semiglutide which I 38:35 didn’t really care for. And with Tresepide, I haven’t plateaued and I’ve been able 38:42 to lose about 25 pounds in um a year and a half and I’ve been able to maintain 38:49 that. Um and I continued to use it because I do have a strong family history of cardiovascular disease. And 38:56 if this could help me so that I don’t follow my family lineage with cardiovascular disease, I am all for 39:03 trying to do that. I’ve watched too many of my family members suffer from this. I’ve lost my dad at a very young age. I 39:09 lost my grandfather at a young age to it. All of their brothers to this. And I don’t want to be that same person. So 39:16 that is why I chose to do that. And I think it’s really important for us to take a look at that and understand that. 39:24 Now, I know this has been a really long podcast and I don’t typically do podcasts this long. I have a whole host 39:31 of information on additional peptides. So, I’m going to break this up for you 39:36 guys and I’m going to do another episode and we’re going to pick up where we left off here with these peptides so that we 39:43 can actually start to dive into different peptides as well. So, check 39:48 out my next podcast show when we’re going to dive into the peptides that 39:54 talk about sexual wellness, immune function, and all the other cool things 39:59 that we can do with peptides. So until then, remember to like, share, and 40:04 subscribe. It really helps us get out to other people and share our information, 40:10 and join us for our next episode as we continue the talk about peptides. 40:15 Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and 40:21 information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its 40:28 management, or our partners. Each affiliate, sponsor, and partner is an 40:34 independent entity with its own perspectives. Today’s content is provided forformational and educational 40:40 purposes only and should not be considered specific advice, whether financial, medical, or legal. While we 40:48 strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique 40:56 circumstances. We encourage you to consult with a qualified professional to address your 41:01 individual needs. Your use of information from this broadcast is entirely at your own risk. By continuing 41:08 to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its 41:14 associates harmless from any claims or damages arising from the use of this 41:20 content. We may update this disclaimer at any time and changes will take effect 41:26 immediately upon posting or broadcast. Thank you for tuning in. We hope you 41:31 find this episode both insightful and thought-provoking. Listener discretion 41:36 is advised.The post Episode 256 – How Peptides Work, Benefits, and FDA-Approved vs Off-Label Use Explained first appeared on Let's Talk Wellness Now.
This issue will review: 1. Real-World Prospective Validation and Economic Evaluation of Deep Learning-based Diabetic Retinopathy Detection from Fundus Photographs: A Systematic Review and Meta- Analysis 2. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial 3. FDA removal of SI for GLP-1s – FDA Announcement Neil Read/John Comment 4. Effectiveness and Safety of Statins in Type 2 Diabetes According to Baseline Cardiovascular Risk: A Target Trial Emulation Study 5. GLP-1 Receptor Agonists and Risk of Optic Nerve or Vision-Threatening Events in Patients with Type 2 Diabetes or Cardiometabolic Diseases: A Meta-Analysis of Randomized Controlled Trials Diabetes Core Update is a monthly podcast that presents and discusses the latest clinically relevant articles from the American Diabetes Association's four science and medical journals – Diabetes, Diabetes Care, Clinical Diabetes, and Diabetes Spectrum. Each episode is approximately 25 minutes long and presents 5-6 recently published articles from ADA journals. Intended for practicing physicians and health care professionals, Diabetes Core Update discusses how the latest research and information published in journals of the American Diabetes Association are relevant to clinical practice and can be applied in a treatment setting. For more information about each of ADA's science and medical journals, please visit Diabetesjournals.org. Hosts: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John J. Russell, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Chair-Department of Family Medicine, Abington Jefferson Health
In this episode, Dr. Osamah Choudhry, Co Founder and CEO of Medivis and neurosurgeon at NYU Langone Health, discusses the evolving role of artificial intelligence and augmented reality in spine and cranial surgery. He shares insights on FDA clearances, distribution strategy, and how next generation navigation technology is improving precision, efficiency, and patient outcomes.
In this episode, Dr. Osamah Choudhry, Co Founder and CEO of Medivis and neurosurgeon at NYU Langone Health, discusses the evolving role of artificial intelligence and augmented reality in spine and cranial surgery. He shares insights on FDA clearances, distribution strategy, and how next generation navigation technology is improving precision, efficiency, and patient outcomes.
For more than a decade, CAR-T therapy has been the miracle of oncology, turning end-stage blood cancers into curable diseases. But the application of these engineered cell therapies is expanding to reset the immune system for patients living with lupus, stiff person syndrome and other autoimmune conditions. And with new frontiers come new rules. In this week’s episode of "The Top Line," Fierce Pharma’s Angus Liu chats with Harpreet Singh, M.D., chief medical officer at Precision for Medicine and a former director of the FDA's Division of Oncology, about a recent article by FDA officials led by CBER Director Vinay Prasad, M.D., laying out the agency’s perspective on its regulation of autoimmune CAR-T therapies. Singh discusses how the agency’s "case-by-case" approach, as indicated in the article, could be similar to—and different from—CAR-T for oncology indications. She also talks about how drug developers should follow existing development experience, as well as prepare for specific requirements for long-term patient follow-up and potential new clinical endpoints from the agency. To learn more about the topics in this episode: FDA signals tailored approach to ‘carefully shepherd’ CAR-T therapy for autoimmune diseases Kyverna gains clear view to first CAR-T approval for autoimmune disease after 'truly remarkable' SPS readout Cabaletta CAR-T wipes out B cells without preconditioning in small autoimmune trial See omnystudio.com/listener for privacy information.
Three House Democrats have introduced the Healthy Hair Act, legislation that would ban formaldehyde in hair straightening and smoothing products nationwide. Supporters say chemical hair products have been linked to higher risks of uterine cancer and other health harms, with Black women disproportionately impacted. The FDA proposed a similar ban in 2023, but it has yet to finalize the rule. Subscribe to our newsletter to stay informed with the latest news from a leading Black-owned & controlled media company: https://aurn.com/newsletter Learn more about your ad choices. Visit megaphone.fm/adchoices
In "Somebody to Lean On," Dr. Osterholm and Chris Dall discuss vaccine updates including the FDA's back-and-forth on the Moderna vaccine, leadership shake-ups at institutions like the CDC, and the current state of measles in the US. Dr. Osterholm will also bring you a respiratory virus update, including current vaccine guidance for flu, COVID and RSV. Op-Ed: The FDA refused to review a flu vaccine, contrary to evidence. Now the agency reversed itself (CIDRAP) The State of US Vaccine Policy (CIDRAP and Unbiased Science)Dentists still write millions of prescriptions a year for an antibiotic with life-threatening risks (CIDRAP) Resources for vaccine and public health advocacy: Voices for Vaccines Families Fighting Flu Vaccinate Your Family Shot@Life Medical Reserve Corps Learn more about the Vaccine Integrity Project MORE EPISODES SUPPORT THIS PODCAST Music: "Beauty Flow" Kevin MacLeod (incompetech.com)Licensed under Creative Commons: By Attribution 4.0 License
Now that the Winter Olympics have wrapped up, the Milan Cortina Paralympic Games kick off on March 6. Dozens of athletes will represent Team USA in sled hockey, skiing, wheelchair curling, and snowboarding. But getting to the Olympics or Paralympics is expensive and costs competitors an average of $12,000 a year. For winter athletes in particular, the costs can be even higher. But first: why the FDA is looking to put the brakes on compounded GLP-1s.
The Trump Administration's rolled out a new, inverted food pyramid that places a stronger emphasis on dairy, red meats and foods higher in fat, while whole grains are at the narrow bottom. This follows HHS Secretary Robert F. Kennedy Jr.'s mission to "Make America Healthy Again" (MAHA), aimed at addressing chronic disease, childhood illnesses and ultra processed foods. The FDA is using the catch-phrase "eat real food" for the campaign they say will ultimately save families money. FOX's Jared Halpern speaks with Kyle Diamantas, the Deputy Commissioner for Human Foods and head of the agency's Human Foods Program, overseeing all FDA nutrition and food safety, who says embracing the new nutritional guidelines will save your family money, and improve your health. Click Here To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit podcastchoices.com/adchoices
Now that the Winter Olympics have wrapped up, the Milan Cortina Paralympic Games kick off on March 6. Dozens of athletes will represent Team USA in sled hockey, skiing, wheelchair curling, and snowboarding. But getting to the Olympics or Paralympics is expensive and costs competitors an average of $12,000 a year. For winter athletes in particular, the costs can be even higher. But first: why the FDA is looking to put the brakes on compounded GLP-1s.
En este episodio de Café en Mano, nos sentamos con una de las figuras culinarias más importantes de Puerto Rico: el Chef Enrique Piñeiro. Hablamos de todo lo que no se ve en televisión. Desde sus inicios cocinando con su abuela y su paso por restaurantes con Estrellas Michelin en Europa, hasta el difícil salto a la fama ganando "Operación Chef".Piñeiro nos cuenta la verdadera odisea de emprender en la isla: cómo tuvo que fracasar con 10 productos antes de crear su exitoso imperio de sofritos y adobos, los rigurosos retos de manufacturar bajo las leyes de la FDA, y la importancia de apoyar a los agricultores locales. Además, nos da su opinión honesta sobre la serie "The Bear", la realidad del maltrato en las cocinas profesionales, y recuerda su histórico encuentro con el legendario Anthony Bourdain.☕ Este episodio es traído a ustedes por Fuse Telecom, internet sin preocupaciones.Sigue al Chef Piñeiro:Instagram: @chefpineiroFacebook: El Chef PiñeiroNo olvides merch de Café en Mano: juanvi.bigcartel.com¡No olvides suscribirte, darle like y dejarnos en los comentarios qué te pareció la entrevista!00:00 - Intro: La fonda de la abuela y la pasión por la cocina03:15 - De Estrellas Michelin en Europa a ganar "Operación Chef"06:30 - El difícil salto a la televisión y el ego profesional12:35 - Emprendimiento: Vender sus negocios para empezar de cero19:40 - La creación de su marca: 10 fracasos antes del sofrito perfecto24:30 - La cruda realidad de manufacturar y cumplir con el FDA27:49 - El reto de conseguir ingredientes de agricultores locales en PR32:20 - ¿Qué define verdaderamente el sabor del paladar puertorriqueño?35:56 - La evolución de la cocina criolla moderna y sofisticada37:20 - Por qué al Chef Piñeiro NO le gustó la serie "The Bear"40:02 - Influencers de comida vs. Chefs de línea de cocina44:45 - El estrés extremo de una cocina profesional (Tickets y Línea)48:57 - Liderazgo: Cómo manejar a tu equipo y evitar el ambiente tóxico52:30 - Conociendo a la leyenda Anthony Bourdain en Puerto Rico56:52 - El impacto económico de consumir local y despedida
You guys have been asking about peptides… and today we're finally breaking it down.In this episode, I sit down with Dr. Zarrabi from Vitality Med Spa in LA to talk about GLP-1 medications, semaglutide, retatrutide, BPC-157, TB-500, and the growing peptide trend taking over social media.Are peptides safe?Should you use them before plastic surgery?What does “stacking” actually mean?Is this FDA approved… or is it the Wild West?We cover:• GLP-1 medications for weight loss (Ozempic-style drugs)• Microdosing and biohacking• Compounding pharmacies vs brand-name pens• Certificate of analysis & quality control• Peptides for healing and recovery• The potential risks nobody talks about• Why you need to check credentials before injecting anythingIf you're a woman in your 30s prepping for surgery and thinking about losing 15–20 pounds first… this episode is for you.As always, we're not here to sell you hype. We're here to give you clarity.FOLLOW THE CONVERSATION
We're marking Rare Disease Month 2026 by highlighting the powerful story of Shanthi Hegde, a young patient advocate working to transform how bleeding disorders are understood, treated, and supported. This work is fueled by her own arduous journey with two rare bleeding disorders and immune dysregulatory syndrome, and an extended diagnostic odyssey marked by dismissal, underdiagnosis, and structural bias. “I was told many times by many providers that these disorders are not common in Indians and that my bruises were there just because I'm brown.” Admirably, Shanthi pushed past this mistreatment, advocated for her medical needs, and devoted herself to tackling a range of issues confronting rare disease patients from mental health access to affordable drug pricing to research equity. In this remarkable Year of the Zebra conversation with host Lindsey Smith, you'll also learn about: Shanti's work with the Hemophilia Federation of America; How gaps extend beyond treatment to include insurance coverage, provider training, and substance use care; What clinicians can do to improve the work they do with rare disease patients. Join us for a conversation that connects patient voice to system change, and explores what real equity for rare disease communities will require. Mentioned in this episode:Hemophilia Federation of AmericaShanthi's LinkedIn Profile If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast
IEC 60601 has been central to medical electrical equipment safety for decades. From the prescriptive approach of the 2nd edition to the risk-based philosophy introduced in the 3rd edition, the standard has continuously evolved to address technological and regulatory complexity.Now, the upcoming 4th edition represents more than an amendment — it signals a structural transformation.This article explores:The Evolution of IEC 60601• Key shifts from the 2nd to the 3rd edition• Why risk management became central• What lessons shaped today's safety philosophyWhat the 4th Edition Brings• A major rewrite rather than incremental updates• The introduction of “atomic requirements”• Structural clarity for manufacturers, test labs, and regulators• Emerging technical considerations (digitalization, AI, cybersecurity, home use)Impact on Existing Devices• Will re-testing be required?• How to assess validity of existing test reports• Transition strategies with notified bodiesIntegration into Design & Documentation• Embedding IEC 60601 into risk management from day one• Required updates in risk files, EMC documentation, labeling, and usability engineering• Practical advice for SMEs with limited resourcesThe Future of IEC 60601• Greater harmonization with ISO 14971 and IEC 62304• Alignment with digital and AI regulatory frameworks• The long-term outlook for medical electrical safetyFor manufacturers, the message is clear:IEC 60601 is not just a testing standard — it is a design and risk management framework that must be integrated early and strategically.Who is Monir El Azzouzi? Monir El Azzouzi is the founder and CEO of Easy Medical Device a Consulting firm that is supporting Medical Device manufacturers for any Quality and Regulatory affairs activities all over the world. Monir can help you to create your Quality Management System, Technical Documentation or he can also take care of your Clinical Evaluation, Clinical Investigation through his team or partners. Easy Medical Device can also become your Authorized Representative and Independent Importer Service provider for EU, UK and Switzerland. Monir has around 16 years of experience within the Medical Device industry working for small businesses and also big corporate companies. He has now supported around 100 clients to remain compliant on the market. His passion to the Medical Device filed pushed him to create educative contents like, blog, podcast, YouTube videos, LinkedIn Lives where he invites guests who are sharing educative information to his audience. Visit easymedicaldevice.com to know more. If you need help implementing QMSR or preparing your teams for FDA inspections, contact: info@easymedicaldevice.com If you are located outside the EU/UK/Switzerland and need an Authorized Representative (and possibly an Importer), we can support you as well.LinkLeo Linkedin: https://www.linkedin.com/in/leoeisnersafetyconsultants/Social Media to followMonir El Azzouzi Linkedin: https://linkedin.com/in/melazzouziTwitter: https://twitter.com/elazzouzimPinterest: https://www.pinterest.com/easymedicaldeviceInstagram: https://www.instagram.com/easymedicaldeviceThis podcast is powered by Podcastics, the easiest platform to create and publish your podcast.
Welcome to OncLive On Air®! I'm your host today, Courtney Flaherty.OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.In today's episode, Rashmi Chugh, MD, sat down with OncLive to discuss the ongoing development of the investigational γ-secretase inhibitor varegacestat (formerly AL102) for patients with desmoid tumors.Chugh is a clinical professor and service chief of Internal Medicine at the University of Michigan Medical School, as well as an oncologist at the University of Michigan Rogel Cancer Center in Ann Arbor.In the exclusive interview, Dr Chugh expanded on the current unmet needs and treatment goals in desmoid tumors, the biologic rationale for γ-secretase inhibition and emerging biomarker considerations, and the potential clinical role of varegacestat based on positive topline data from the phase 2/3 RINGSIDE trial (NCT04871282).Of note, submission of a new drug application to the FDA for this agent in progressing desmoid tumors is planned for the second quarter of 2026._____That's all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.If you liked today's episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!Thanks again for listening to OncLive On Air.*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.This content is a production of OncLive; this OncLive On Air podcast episode is supported by funding, however, content is produced and independently developed by OncLive.
If you thought Part 1 with Paul Eftang and Matt Harrier was wild — an FDA raid with guns drawn, two years of legal battles, and a crusade against supplement fraud — Part 2 is where it gets genuinely useful. Episode #206 of the PricePlow Podcast picks up right where we left off, this time diving deep into the actual ingredients and products that Nootropics Depot has developed, sourced, and standardized over more than a decade of pharmaceutical-grade R&D. Recorded at Nootropics Depot’s headquarters in Tempe, Arizona, Paul and Matt walk us through tongkat ali’s redemption arc from “gas station boner pill” to clinically meaningful testosterone support, explain why almost every mushroom supplement on the market is mislabeled, detail a 6-year journey to bring a real Ecklonia cava to market, and reveal how a bacopa extract binds to the same receptor as psilocybin. Along the way, they cover cistanche, lion’s mane, Tribugen, a prebiotic fiber system, a novel protein concept, and an industry-wide testing fraud landscape that makes their product philosophy make total sense. Sign up for Nootropics Depot news alerts on PricePlow and subscribe to the PricePlow Podcast on your favorite platform before diving in. https://blog.priceplow.com/podcast/nootropics-depot-products-206 Video: Paul Eftang and Matt Harrier of Nootropics Depot Break Down the Products https://www.youtube.com/watch?v=LkZ-GDzEQRo Detailed Show Notes: Paul Eftang and Matt Harrier of Nootropics Depot on Ingredients, Innovation, and Industry Fraud (0:00) – Introductions (0:15) – Tongkat Ali: From “Gas Station Boner Pill” to Top Seller (7:30) – The TRT Problem: Are Doctors Telling Men They’re Broken? (10:30) – EurycoMax: The Optimized Tongkat Ali Stack (12:00) – Lance Dreher: A 70-Year-Old Mr. Universe Case Study (14:30) – Cell Culture Research at Nootropics Depot (17:45) – Lion’s Mane: The Mycelium vs. Fruiting Body Debate (23:45) – Building Reference Standards from Scratch (26:30) – Erinamax: The World’s First Erinacine A Product (28:30) – Nerve Growth Factor and Real Consumer Stories (30:45) – Tiger Milk Mushroom and Traditional Wisdom (36:30) – Ecklonia Cava: A 6-Year Quest (44:00) – Dieckol: The UV Protection Discovery (47:00) – Why Most Ecklonia Cava on the Market Is Fake (52:00) – Consumer Expectations vs. Long-Term Ingredient Reality (55:00) – Cistanche: The Most Underrated Ingredient (59:15) – Cognance: Bacopa Reinvented with Ebelin Lactone (1:01:30) – Solving Bacopa Anhedonia (1:03:00) – The Sabroxy-Cognance-Saffron Stack (1:05:00) – Infinifiber and the Akkermansia Ecosystem (1:10:15) – The Protein Frontier and Future Ingredients (1:16:15) – AI as an R&D Tool (1:21:15) – Tribulus, Protodiosein, and the DHT Angle (1:22:45) – The Turkesterone Exposé (1:29:00) – Amazon Fraud and Industry-Wide Testing Failures (1:31:30) – Third-Party Lab Shopping and Dry Labs Where to Follow and Learn More Connect with Paul Eftang, Matt Harrier, and Nootropics Depot Matt Harrier … Read more on the PricePlow Blog
The Trump Administration's rolled out a new, inverted food pyramid that places a stronger emphasis on dairy, red meats and foods higher in fat, while whole grains are at the narrow bottom. This follows HHS Secretary Robert F. Kennedy Jr.'s mission to "Make America Healthy Again" (MAHA), aimed at addressing chronic disease, childhood illnesses and ultra processed foods. The FDA is using the catch-phrase "eat real food" for the campaign they say will ultimately save families money. FOX's Jared Halpern speaks with Kyle Diamantas, the Deputy Commissioner for Human Foods and head of the agency's Human Foods Program, overseeing all FDA nutrition and food safety, who says embracing the new nutritional guidelines will save your family money, and improve your health. Click Here To Follow 'The FOX News Rundown: Evening Edition' Learn more about your ad choices. Visit podcastchoices.com/adchoices
Want more info on Toxic Mold? https://moldjacked.com/#MoldJacked #moldtoxicity In this eye-opening presentation, Dr. Osborne discusses the growing concern of mold-related illnesses, warning that it could become a major epidemic in the U.S. He explains how symptoms go beyond typical mold allergies, touching on mycotoxicosis, skin rashes, and unexplained fevers. Sharing personal stories from his own experience with mold exposure, Dr. Osborne addresses the challenges of diagnosing these issues, often mistaken for other conditions like viruses or childhood illnesses. He also critiques the limitations of traditional mold testing and emphasizes the need for greater awareness of the dangers posed by mycotoxins, which can contribute to severe health problems like autoimmune diseases and cancer. Dr. Osborne advocates for a holistic recovery approach, including dietary changes and psychological support, and urges viewers to educate others on the risks of mold exposure to help prevent a health crisis in the future.For more info, visit moldjacked.comGluten Sensitive? Take the quiz & Join Our Community ▶https://www.glutenfreesociety.org/gluten-sensitivity-intolerance-self-test/Get my quick start guide on going gluten free: https://www.glutenfreesociety.org/how-to-go-gluten-free/Nutritional Crash Courses Playlist: https://www.glutenfreesociety.org/nutritionGet Gluten Free Supplements: https://www.glutenfreesociety.org/shop-home/No Grain No Pain the Book: https://www.glutenfreesociety.org/NoGrainNoPainGlutenology Masterclass (Ultimate Guide): https://glutenology.net/registrationTo connect with Dr. Osborne visit:On the web: https://drpeterosborne.com/Facebook: https://www.facebook.com/DoctorPeterOsborne/TikTok: https://www.tiktok.com/@drpeterosborneInstagram: https://www.instagram.com/drosborneTwitter: https://twitter.com/glutenologyPinterest: https://www.pinterest.com/docosborne/Podcast:Apple Podcasts: https://podcasts.apple.com/us/podcast/dr-osbornes-zone/id1706389688?uo=4Spotify: https://open.spotify.com/show/4Zdf07GgpRAVwlSsYvirXTAmazon Music/Audible: https://music.amazon.com/podcasts/20d71b2e-3554-4569-9d5b-4259785cdc94Google Podcasts: https://www.google.com/podcasts?feed=aHR0cHM6Ly93d3cuc3ByZWFrZXIuY29tL3Nob3cvNTkwNjcwNC9lcGlzb2Rlcy9mZWVkiHeart Radio: https://iheart.com/podcast/119388846Dr. Peter Osborne is one of the most sought after alternative and nutritional experts in the world. A Diplomate with the American Clinical Board of Nutrition, a graduate of Texas Chiropractic College, and a doctor of pastoral science, Dr. Osborne is one of the world's leading authorities on gluten, nutrition, and natural health. He is the founder of GlutenFreeSociety.org, one of the world's largest informational sites on gluten sensitivity. In addition, he is the author of the best selling book, No Grain No Pain, published by Touchstone (Simon & Schuster). His work has been featured by PBS, Netflix, Amazon, Fox, U.S. News, New York Post, and many other nationally recognized outlets.For collaborations please email: glutenology@gmail.comAny information on diseases, treatments, nutrition, or other health related topics from this channel are for educational purposes only, and should not be considered a substitute for advice provided by your doctor or healthcare provider. Bottom line...if you have health issues, you should always seek professional medical guidance.Products and supplements discussed in this video have not been evaluated by the FDA. They are not intended to treat, cure, or diagnose. Dr. Osborne is an Amazon affiliate, and many earn from qualifying purchases. For more information, visit us at https://www.glutenfreesociety.org/ or call 281-903-7527
Psychiatrist, internist, and addiction medicine specialist Muhamad Aly Rifai discusses his article "Psychedelic-assisted therapy: science, safety, and regulation." Muhamad explores the complex landscape of psychedelic medicine, balancing the growing public interest with the necessity of rigorous FDA oversight and safety protocols. The conversation examines the distinction between classic psychedelics like psilocybin and dissociatives like ketamine while highlighting why "set and setting" are critical for therapeutic success in treating depression and trauma. Muhamad emphasizes that these powerful agents are not simple pill swaps but require structured psychological support to translate peak experiences into lasting behavioral change. Discover why the path to effective treatment relies on transparent regulation and clinician humility rather than unsupervised experimentation. Partner with me on the KevinMD platform. With over three million monthly readers and half a million social media followers, I give you direct access to the doctors and patients who matter most. Whether you need a sponsored article, email campaign, video interview, or a spot right here on the podcast, I offer the trusted space your brand deserves to be heard. Let's work together to tell your story. PARTNER WITH KEVINMD → https://kevinmd.com/influencer SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended
On this episode, Jared takes a deep dive into Biocidin, a practitioner-trusted botanical formula long used in functional and integrative wellness settings. Learn what makes this multi-herb blend unique and why it's often included in protocols designed to support oral health, gut health, immune resilience, and overall microbial balance. Jared explains biofilms in simple terms, why they matter for long-term wellness, and how botanical formulas like Biocidin are used to help maintain a balanced microbiome throughout the body. From the mouth and throat to the digestive tract and beyond, this episode explores real-world applications, research insights, and practical considerations for using multi-botanical support as part of a comprehensive wellness strategy. Part one focuses on education and understanding, while part two will cover how practitioners typically structure supportive protocols.Products:Biocidin and Dentalcidin ProductsVitality Radio POW! Product of the Week: Utzy Naturals Magnositol and Utzy Naturals Coll-U-Gen Get 35% off one bag or 45% off two or more bags (mix and match OK!) No Code Needed! (while supplies last)Additional Information:#555: From Gut to Gums: Mastering Microbial Balance Using Biocidin with Dr. Shawn Manske#617: Microbiome Balance from Mouth to Gut: Protocols for Clearing and Rebuilding with Biocidin – Part 2Visit the podcast website here: VitalityRadio.comYou can follow @vitalitynutritionbountiful and @vitalityradio on Instagram, or Vitality Radio and Vitality Nutrition on Facebook. Join us also in the Vitality Radio Podcast Listener Community on Facebook. Shop the products that Jared mentions at vitalitynutrition.com. Let us know your thoughts about this episode using the hashtag #vitalityradio and please rate and review us on Apple Podcasts. Thank you!Just a reminder that this podcast is for educational purposes only. The FDA has not evaluated the podcast. The information is not intended to diagnose, treat, cure, or prevent any disease. The advice given is not intended to replace the advice of your medical professional.
In this Winter News & Notes episode of The Celiac Project Podcast, Mike and Cam share powerful listener updates and real life celiac journeys. From insurance battles and refractory celiac disease to mental health, OCD, and navigating college gluten free, this episode highlights both the challenges and the progress happening in the community. They also discuss advocacy efforts around FDA labeling and helpful resources for checking whether medications are gluten free.
On this episode of The Gist Healthcare Podcast, we cover the FDA's fast track for rare disease treatments, the end of two major healthcare labor strikes and a measles outbreak in South Carolina nearing 1,000 cases. Hosted on Acast. See acast.com/privacy for more information.
#200 - Miracle Cure or Internet Hype? The Truth About Castor Oil Castor oil is having a moment. Scroll social media for five minutes and you'll see it: “Cured my endometriosis.” “Detoxed my liver.” “Regrew my hairline.” “Healed… well, everything.” And when something is suddenly the solution to literally every problem… it's time to pause. Because while castor oil is absolutely powerful, not every claim floating around the internet deserves your blind trust (or all of your body parts). In this episode, I break down what castor oil actually is, what it's scientifically supported for, what I personally use it for, and what I absolutely would not recommend—especially if you're pregnant or thinking about putting it near your eyeballs. If you've been curious about castor oil packs, anti-aging benefits, hair growth hacks, stretch mark reduction, or lymphatic detox claims… this episode is your grounded, evidence-based (with a dash of anecdotal honesty) guide. What You'll Learn in This Episode What castor oil is made of (and why omega-9 fatty acids matter) FDA-approved uses vs. influencer folklore Whether castor oil actually helps with constipation Skin barrier repair, anti-aging, and collagen support Hair growth, scalp health, and rosemary oil synergy Castor oil for scars, stretch marks, arthritis, and cracked heels The truth about castor oil packs for liver detox Regular vs. Jamaican black castor oil—is there a difference? Side effects, safety, and when to absolutely avoid it Timestamps 00:00 – Castor oil: miracle cure or marketing frenzy? 01:00 – Why the FDA cracked down on exaggerated claims 02:00 – What castor oil actually is (hello, omega-9 fatty acids) 04:30 – What it's officially approved for 05:00 – Would I drink it for constipation? 06:30 – Traditional uses: skin conditions, infections, inflammation, lymphatic support 07:30 – Skin benefits that actually make sense 08:00 – Fine lines, wrinkles, and collagen support (why it may help) 09:00 – How to use it for hair growth 10:30 – Acne: helpful or hormonal disaster? (Bio-individuality matters) 12:00 – Castor oil packs for liver detox—worth it? 13:00 – Thyroid application (yes, I use it for Hashimoto's support) 14:00 – Stretch marks & scars: how to use heat to enhance absorption 16:00 – Anti-aging layering method (this is worth the price of admission) 17:00 – Lips: hyaluronic acid + castor oil combo 18:00 – Cracked heels, cuticles, and nail growth 20:00 – The fern experiment (because why not?) 21:00 – Jamaican black castor oil vs. regular: which is better? 22:00 – Side effects and when not to use it 23:00 – Pregnancy warning (seriously, a hard no) 24:00 – My honest verdict Let's Talk About What's Real Castor oil is rich in ricinoleic acid—an omega-9 fatty acid with anti-inflammatory properties. That's the magic. It's thick. It's deeply emollient. It seals moisture in like a champ. Which makes it excellent for: Dry skin Eczema-prone areas Crepey skin in perimenopause and menopause Fine lines (temporarily plumping through hydration) Cracked heels Dry cuticles Scalp nourishment And when you layer it correctly, it acts like a sealant to hold hydration in. I personally use it nightly on my face, neck, thyroid area, lips, and brows. Am I shiny before bed? Yes. Do I care? Not even a little. What I'd Be Careful With Internal use for constipation (very effective but not my first-line recommendation) Anything near your eyes (I woke up with red, burning, and irritated eyes) Vaginal dryness or sensitive internal use (research first, please) When To Never Use It Pregnancy (it induces labor) Castor Oil & Hormones As estrogen drops in perimenopause and menopause, skin becomes thinner, drier, and less elastic. This is where castor oil shines—literally and figuratively. It supports: Skin barrier repair Moisture retention Elasticity appearance That “spring back” we start to lose Is it Botox? No. Is it still amazing and affordable? Absolutely. Bottom Line Is castor oil a cure-all? Nope. Is it a potent, multi-use, low-risk tool? Yes. In a world where we're constantly sold $200 serums and complicated 12-step regimens, there's something refreshing about a humble glass bottle that's been used for centuries. If you try it: Buy organic Make sure it's in a dark glass bottle Patch test first Use cotton (preferably organic), not polyester, when covering treated areas And maybe—just maybe—pour it into something beautiful so you'll actually remember to use it. One More Thing Pretty Well was shared more than 94% of other shows in Spotify Wrapped this year. That's because of you. You share it. You text it. You send it to friends who need better information without the hype. And that means everything to me. If this episode helped you to decode the castor oil craze (or prevented you from putting it in your eyes), do me a favor and share it with a friend.
Autism, Functional Medicine, and Personalized Interventions: A Conversation with Theresa Lyons, PhD, a Yale-trained scientist and medical strategist who became an autism expert after her daughter's diagnosis and now runs AWEtism.net. Lyons describes dissatisfaction with conventional guidance that offers limited drugs for irritability and primarily ABA (Applied Behavioral Analysis), which is insurance-covered, often recommended at 40 hours/week, uses extrinsic rewards, and may help some skill-learning but has controversies and limitations for social development; she contrasts newer approaches such as RDI (Relationship Development Intervention) and PRT (Pivotal Response), which aim to build intrinsic motivation but are typically not covered by insurance. The discussion covers autism heterogeneity, changes in diagnostic categories (e.g., Asperger's folded into autism), and research including a Boston Children's Hospital study reporting 37% of children in a cohort lost their autism diagnosis over time (diagnosis based on observation). Lyons addresses debates about rising autism prevalence, noting multiple potential contributors and rejecting single-cause explanations, while citing risk-factor examples such as family autoimmune history and air pollution exposure. She outlines a functional medicine “why” approach using constipation as an example (root causes vs. symptomatic treatment), and emphasizes basic, low-risk steps such as evaluating diet, inflammation, hydration/electrolytes, and blood work for nutrients. Specific topics include gluten-free approaches (mechanisms involving gut permeability, immune burden, and CNS effects), dairy/inflammation, vitamin D deficiency and monitoring, melatonin as a well-studied short-term aid in autism (considered safe for a couple of years in studies) while still seeking underlying causes, and omega-3 fatty acids for focus and inflammation. Lyons explains leucovorin (folinic acid, prescription vitamin B9) as a targeted approach for children with folate receptor antibodies (reported in ~70% of autistic children), discusses the value and cost (~$300) of specialized testing from one U.S. lab, and notes reports of major speech and behavior improvements in responders, with dosing nuances. The episode also reviews evidence and cautions around the microbiome, including fecal microbiota transplant (FDA-approved for C. difficile; discussed as having an ~80% response rate in autism-related studies when gut issues are a key driver, but with major donor/compatibility considerations) and probiotics (some small trials and high costs). Other themes include “clean eating,” organic foods and toxin-load considerations tied to genetic detoxification vulnerabilities, discussion of acetaminophen/Tylenol in pregnancy in the context of glutathione pathways and personalized risk, and using genetics to guide interventions. Lyons warns that analysis of top autism TikTok videos found ~70% were inaccurate or overdramatized, recommending social media only for ideas, not decision-making. She also highlights parent stress, citing emerging research on increased PTSD risk among autism parents, and emphasizes support and community. Lyons advises parents to understand their child's specific health drivers and match them to appropriately specialized clinicians, noting her curated doctor listings in The Lyons Report.
Jax and John are on a mission to make gluten labeling clear and safe for everyone. With so many misleading labels, it's crucial for us to advocate for change. Imagine knowing exactly what's in your food! That's what this is all about—ensuring safety and transparency for those of us with celiac disease.Let's share our stories, raise awareness, and push the FDA to listen. Your voice matters!Together, we can make a difference.
What if the most important person in your dental office isn't the one holding the drill?The dental hygiene profession is undergoing a massive transformation that reaches far beyond simple cleanings and into the realm of life saving medical integration. This conversation features Lancette VanGuilder, President of the American Dental Hygienists Association, who breaks down why the future of oral health depends on giving hygienists more autonomy and better license portability across state lines. She shares fascinating insights into how these professionals are now at the front lines of identifying systemic issues like sleep apnea and why a shift toward self regulation is essential for the survival of the workforce. From the challenges of rural healthcare to the importance of building a supportive office culture, this discussion explores how the next generation of hygienists is redefining what it means to provide comprehensive patient care in a modern world.Connect with Lancette
Last time we talked about kidney xenotransplantation, we were joined by Towana Loony and Tim Andrews, who shared their personal experiences with receiving a xenotransplant. Today, two doctors who helped propel xenotransplantation forward, Dr. Vineeta Kumar and Dr. Leonardo Riella, are here to explain the science and what comes next. This episode is supported by eGenesis and United Therapeutics In this episode we heard from: Vineeta Kumar is the lead nephrologist for UAB's Living Kidney Donor and Incompatible Kidney Transplant programs. She is an expert in kidney transplantation, living kidney donation, incompatible kidney transplant, kidney paired donation and cardiovascular outcomes after kidney transplantation. Kumar also engages in research in the prevention, treatment and prognosis of antibody mediated rejection. She has been named a "Top Doctor" by U.S. News & World Report each year since 2012. She has been lead facilitator of the UAB Schwartz Rounds since 2009, a program that brings together nurses, physicians, social workers, and other providers to discuss delivery of compassionate care. She was awarded the Brewer-Heslin Endowed Award for Professionalism in Medicine for the highly skilled and compassionate medical care she provides to her patients. Kumar was recently named "Best Educator" by the 2018, 2019 and 2020 UAB Medical School classes. She has previously served on the Education Committee for the American Society of Transplantation. Leonardo V. Riella, M.D., Ph.D. is the Harold and Ellen Danser Endowed Chair in Transplant Surgery at Harvard Medical School and the Medical Director of Kidney Transplantation at Massachusetts General Hospital. His research focuses on mechanisms of immune regulation and the development of novel therapies to promote transplant tolerance. In addressing kidney disease recurrence post-transplantation, he founded and leads the TANGO Consortium, the largest global effort dedicated to studying glomerular disease recurrence. In March 2024, Dr. Riella led the world's first successful kidney xenotransplant from a gene-edited pig into a living human. He now leads the first FDA-approved pilot study in kidney xenotransplantation and is conducting high-dimensional immune profiling studies to characterize the human xeno-immune response and guide immunosuppressive strategies. Find out more about Dr. Riella's research here. Additional Resources Xenotransplantation Information Do you have comments, questions, or suggestions? Email us at NKFpodcast@kidney.org. Also, make sure to rate and review us wherever you listen to podcasts.
Announcements: SOTU @5:47 Follow-ups: FDA does a 180, decides it will review Moderna's mRNA vaccine @8:51 Fetterman at SOTU @9:40 Religious Nonsense: Tennessee bill would require public schools to teach the Bible @9:45 Earlier this week, another big Texas school district said “no, thanks” @11:24 Hegseth invited pastor to lead Pentagon prayer service @12:10 State of the Union update @14:23 PRRI released a new report on Christian Nationalism @15:55 News: Armed Man Is Fatally Shot at Mar-a-Lago @18:15 Trump Considers Targeted Strike Against Iran @22:22 Jared's take on the Men's Hockey team @26:19 Ambassador Mike Huckabee suggests Israel has God-given right to Middle East @26:47 Andy Win arrested @29:41 Peter Mandelson, Ex-Ambassador to the U.S. Arrest @33:41 Politics: DoW Christian Service Draws Complaints @35:37 Ohio mayor arrested on voyeurism charges @42:34 Health/Medicine/Science: NIH Director Jay Bhattacharya the new interim director of the CDC @48:56 Uproar in MAHA because glyphosate @49:37 Skeptical Inquirer Experts warn about NIH director @57:14 U.S. Creating a brand-new parallel WHO org @57:43 Final Stories: Flavor Flav invites USA women's hockey team to 'real celebration' @58:25
On today's Celiac Project Podcast:In this Winter News & Notes episode of The Celiac Project Podcast, Mike and Cam share powerful listener updates and real life celiac journeys. From insurance battles and refractory celiac disease to mental health, OCD, and navigating college gluten free, this episode highlights both the challenges and the progress happening in the community. They also discuss advocacy efforts around FDA labeling and helpful resources for checking whether medications are gluten free.Listen to the full episode here: https://celiacprojectpodcast.libsyn.com/I would love to hear from you! Leave your messages for Andrea at contact@baltimoreglutenfree.com and check out www.baltimoreglutenfree.comInstagramFacebookGluten Free College 101Website: www.glutenfreecollege.comFacebook: http://www.Facebook.com/Glutenfreecollege Hosted on Acast. See acast.com/privacy for more information.
In this episode of Data in Biotech, Ross Katz sits down with Kyle Smith and Jacob Mayer from Aprecia Pharmaceuticals to explore how 3D printing is transforming pharmaceutical manufacturing. They dive into the unique binder jetting process, in-cavity printing, and how real-time data and automation are enabling agile, scalable, and precise drug production. Discover how Aprecia's approach is changing the game for clinical trials and personalized medicine. What you'll learn in this episode: >> How Aprecia developed the world's first FDA-approved 3D printed drug >> Why binder jetting stands out among 3D printing methods in pharma >> How in-cavity 3D printing enables real-time tablet-level data collection >> The future of closed-loop control and digital twins in drug manufacturing >> Why 3D printing is key to agile, distributed, and personalized pharma production Meet our guests: Kyle Smith is President and COO of Aprecia Pharmaceuticals, leading strategic growth and innovation in GMP-regulated pharma manufacturing. With 12+ years at Aprecia, he brings deep expertise in engineering, operations, and technology transfer. Jacob Mayer is Director of Engineering Innovation at Aprecia Pharmaceuticals. With a decade of experience across automation, additive manufacturing, and life sciences, he leads the advancement of 3D printing technologies and integrated pharma systems. About the host Ross Katz is Principal and Data Science Lead at CorrDyn. Ross specializes in building intelligent data systems that empower biotech and healthcare organizations to extract insights and drive innovation. Connect with our guests: Sponsor: CorrDyn, a data consultancyConnect with Jacob Mayer on LinkedIn Connect with Kyle Smith on LinkedIn Connect with us: Follow the podcast for more insightful discussions on the latest in biotech and data science.Subscribe and leave a review if you enjoyed this episode!Connect with Ross Katz on LinkedIn Sponsored by… This episode is brought to you by CorrDyn, the leader in data-driven solutions for biotech and healthcare. Discover how CorrDyn is helping organizations turn data into breakthroughs at CorrDyn.
It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: big updates for stem cell and islet transplants, new pen option for Zepbound, an implantable insulin pump moves forward and more! Announcing Community Commericals! Learn how to get your message on the show here. Learn more about studies and research at Thrivable here Please visit our Sponsors & Partners - they help make the show possible! Omnipod - Simplify Life All about Dexcom T1D Screening info All about VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Episode transcription with links: Welcome! I'm your host Stacey Simms and this is an In The News episode.. where we bringing you the top diabetes stories and headlines happening now. A reminder that you can find the sources and links and a transcript and more info for every story mentioned here in the show notes. Quick reminder: I'm just back from MNO DC and I'm exhausted. But it's the best kind of tired. We had an incredible time – hope you can join us in Nashville. With a reminder that we have our first Club 1921 in Nashville – that's our educational dinner series for HCPs and patient leaders. All the info is over at diabetes-connections.com events/ Okay.. our top story this week: XX An "immune system reset" eliminated Type 1, diabetes in mice in a study conducted at Stanford Medicine without immune suppressant medications. This was a combined transplant of blood stem cells and insulin-producing pancreatic islet cells from a donor whose immune profile did not match the recipient. The dual transplant approach both restored insulin production and retrained the immune system. For the full six months of the experiment, the animals did not need insulin injections or immune suppressive medications. Challenges remain using this approach to treat Type 1 diabetes. Pancreatic islets can be obtained only after death of the donor, and the blood stem cells must come from the same person as the islets. It is also unclear whether the number of islet cells typically isolated from one donor would be enough to reverse established Type 1 diabetes. But the researchers are working on solutions, which could include generating large numbers of islet cells in the laboratory from pluripotent human stem cells, or finding ways to increase the function and survival of transplanted donor islet cells. https://scitechdaily.com/stanford-scientists-cure-type-1-diabetes-in-mice-without-insulin-or-immune-suppression/ XX An electronic implant interlaced with islet cells is being looked at to treat type 1. Researchers at the University of Pennsylvania School of Medicine worked with engineers at Harvard University to combine stem-cell biology with soft electronics. They inserted an ultrathin, flexible mesh of conductive wires — thinner than a human hair — into developing pancreatic tissue. As the cells assembled into clusters, the mesh became woven through them. The electronics can record the faint electrical signals produced by the cells that control insulin release. They can also deliver small pulses of electricity back to the cells. After several days, the cells began to behave more like mature islets. Their internal signalling shifted, neighbouring cells started working in concert and insulin release became stronger and better timed. Very early on here – and the transplanted cells still need to be protected from being attacked by the immune system. https://www.thetimes.com/uk/science/article/first-cyborg-pancreas-implants-type-1-diabetes-nxkv8r0fp?gaa_at=eafs&gaa_n=AWEtsqeJYYUF9TMR-GgGUG92hPyog-ISeiqGIgdyaaIKKcpvhtoftGiUaaOtQeG0NWI%3D&gaa_ts=699c50d4&gaa_sig=w-PQ0ArosZSznYDSWEzt8aQg4WC0FF5ZFRt9NedO5sSTL2FyWzupH8eSG7RCy2S8TQnlHOeKCudANWm1MNI59w%3D%3D XX Katie Beth (hand) Eledon trial – aaron kowalski post linkedin. Last fall we told you about promising results from Eledon's drug to prevent islet transplantation rejection in type 1 diabetes. The first six patients no longer had to inject or infuse insulin.. the trials continue and this month one of the patients – Katie Beth Hand – began posting about her experiences one month in, on social media, she says she's off basal insulin already and in range 99 percent of the time. She is also encouraging people to learn more about support the islet act https://lnkd.in/e8pQ7_Y7 XX This is a bill introduced last November which would change the wording on pancreatic cell transplants. The problem is that islets are classified as drugs rather than organs, making transplantations difficult for medical teams and centers to preform due to accessibility. Insurance companies are also less likely to provide reimbursements for treatment, which can cost hundreds of thousands of dollars. The official Journal of The Transplantation Society estimates the cost at about $140,000. The bill went to the senate committee of Health, Education, Labor, and Pensions in early November. No other action has been taken since then. https://www.wtoc.com/2026/02/19/bluffton-family-advocates-islet-act-help-diabetic-son/ XX Big change for the obesity drug Zepbound – now available in the multi dose KwikPen. This is a month's worth of doses in a single pen.. and it's multi dose – you can adjust it. Cash-paying patients can get the multi-dose device, called KwikPen, on the company's direct-to-consumer website, LillyDirect. Prices start at $299 per month for the lowest dose level. Until now, you could only get zepbound in a single dose auto injector or a sing dose vial. In a release, Lilly said the Food and Drug Administration approved a label expansion for Zepbound to include the multi-dose device. The KwikPen is already used for other drugs, such as Lilly's popular diabetes medication, Mounjaro – which is the same medication as zepbound, they're both tirzepitide. https://www.cnbc.com/2026/02/23/eli-lilly-launches-zepbound-obesity-drug-pen-one-month-doses.html XX For years, researchers have observed that people who live at high elevations, tend to develop diabetes less often than those at sea level. Although the trend was well documented, the biological explanation behind it was unclear. Scientists now say they have identified the reason. Their research shows that in low oxygen environments, red blood cells begin absorbing large amounts of glucose from the bloodstream. Their work showed that when oxygen is limited, red blood cells use glucose to generate a molecule that helps release oxygen to tissues. This process becomes especially important when oxygen is in short supply. The researchers also found that the metabolic benefits of prolonged hypoxia lasted for weeks to months after mice were returned to normal oxygen levels. They then evaluated HypoxyStat, a drug recently developed in Jain's lab that mimics low oxygen exposure. HypoxyStat is taken as a pill and works by causing hemoglobin in red blood cells to bind oxygen more tightly, limiting the amount delivered to tissues. In mouse models of diabetes, the medication completely reversed high blood sugar and outperformed existing treatments. https://www.sciencedaily.com/releases/2026/02/260221060952.htm XX Watching this one closely – Portal Diabetes gets FDA breakthrough device designation for its implantable insulin pump system. This is a system that includes not just a device that's implanted into the abdomen, but also a new, temperature stable insulin. It will work with – quote – "modern" CGM technology with a fully closed loop - and aims to deliver a functional cure for type 1. While reports say Portal's system is the first in the US – there was an implantable pump developed and used by about 500 people worldwide, including about 100 in the US – by MiniMed. Medtronic bought the company and in 2007 they stopped that program. Portal Diabetes expects to begin clinical trials on its combination system around the fourth quarter of 2027. https://www.drugdeliverybusiness.com/portal-diabetes-fda-breakthrough-implantable-insulin-pump/ XX Sequel Med Tech and Senseonics (NYSE:SENS) today announced the full U.S. launch of their CGM and insulin pump integration. That's the eversense cgm and twist pump. Sequel said its full launch with Eversense 365 makes twiist available with two compatible CGMs. twiist also pairs with the Abbott FreeStyle Libre 3 Plus sensor. Eversense 365, an implantable system, rests under the skin for the duration of a year. Users can change its external, silicone-based adhesive daily with almost no skin reactions. https://www.drugdeliverybusiness.com/sequel-senseonics-full-launch-twiist-eversense/ XX Right back with a Dexcom update, and a look at which type of diet reduces insulin use overall.. right after this: -- Back to the news.. Dexcom is watching for expanded Medicare coverage of its continuous glucose monitors to people with Type 2 diabetes who don't take insulin. CEO Jake Leach told investors on Thursday that the company has been "sitting here waiting for a coverage decision" from the Centers for Medicare and Medicaid Services Dexcom started to see commercial coverage unlock for Type 2, non-insulin users toward the end of last year, Leach said. He expects broader Medicare coverage for that group would allow nearly 12 million people to access CGMs. In the meantime, the American Diabetes Association updated its guidelines last year to recommend clinicians consider using CGMs for Type 2 diabetes when patients are taking glucose-lowering medications other than insulin. Leach said that real world data the company has been generating supports that decision, and that Dexcom has launched a registry for non-insulin users. https://www.medtechdive.com/news/dexcom-seeks-expanded-medicare-coverage-of-cgms-for-type-2-diabetes/812223/ XX Medtronic's separation of MiniMed is not yet complete.. but continues to move forward. The company has submitted their next pump – MiniMed Flex – to the FDA. This is a pump smaller than the 780G but uses the same reservoirs and infusion sets. It will also work with both the Simplera Sync and Instinct sensors. Medtronic also began a U.S. pivotal study for Vivera, its third-generation algorithm for automated insulin delivery. It also remains set to submit its MiniMed Fit patch pump system to the FDA by the coming fall. https://www.drugdeliverybusiness.com/medtronic-submits-minimed-flex-fda-q3/ XX A study modelling how genes may influence a child's body mass index over time has found that BMI at age 10 and overall growth rate between ages one and 18 might be important factors, as the two are more likely linked to diabetes, high cholesterol, and heart disease in later life. Nearly 66,000 BMI measurements from around 6,300 children and adolescents aged one to 18 were analysed to understand the role of genes. "Future research is needed to help identify the most effective ages to prevent obesity or poor growth for long-term benefit." https://www.ndtv.com/health/bmi-at-age-10-growth-rate-up-to-age-18-are-important-factors-for-diabetes-heart-disease-study-11125146 XX A low-fat vegan diet—without cutting calories or carbs—may help people with type 1 diabetes significantly reduce how much insulin they need. In a new analysis published in BMC Nutrition, participants following the plant-based plan lowered their daily insulin use by 28%, while those on a portion-controlled diet saw no meaningful change. Researchers say the reduced insulin requirement likely reflects improved insulin sensitivity. The original 2024 study reported additional benefits from the vegan diet. Participants lost an average of 11 pounds and showed improvements in insulin sensitivity and glycemic control. Cholesterol levels and kidney function also improved among those following the plant-based plan. https://www.sciencedaily.com/releases/2026/02/260212234212.htm XX Interesting little tidbit from the Winter Olympic Games.. the World Anti-Doping Agency (WADA) was monitoring GLP drug use. An advisory group that makes recommendations about WADA's list of prohibited substances discussed the status of GLP-1 medications, and added semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro, Zepbound) to its monitoring program That means patterns of use of these drugs will be tracked both in and out of competition. The finding will be used to make recommendations about whether GLP-1 agonists should be added to the prohibited list, the spokesperson explained. While GLP-1 drug use is not currently prohibited, that could change before the next Summer Olympic Games in Los Angeles in 2028, he noted. https://www.medpagetoday.com/popmedicine/cultureclinic/119770 XX That's it for in the news!
Today, Ali talks to Barbara Ginty, host of the Future Rich podcast, for a special crossover episode to share her deeply personal fertility journey — and to talk honestly about the emotional and financial realities of IVF. Barbara froze her eggs in her 30s, not knowing exactly when or how she might use them. Seven years later, she returned to those frozen eggs and went through IVF — and now, as this episode airs, she's on the brink of welcoming her first baby. Barbara shares what it was like to trust a decision she made years earlier, the uncertainty of the process, and the surreal feeling of finally reaching this moment. Barbara also turns the mic on Ali, who opens up about her secondary infertility and IVF journey, including the complicated emotions that can come with trying to grow your family after already having a child. For more, check out www.futurerichpodcast.comEPISODE SPONSORS: THE WORK OF ART BOOK SERIESAli's Children's Book Series about IVF, IUI and Family Building Through Assisted Reproductive Technology https://www.infertileafgroup.com/booksThe 3-book bundle is now just $49 (normally $79)!The latest book in the Work of ART series, “You Are a Work of ART," is for every kiddo born through ART -- and the people who love them.PHERDALIG: @pherdal_sciencePherDal is the world's first and only FDA-cleared, sterile, at-home insemination kit designed to help people build their families in the comfort of home. Created by parents who've been there, PherDal is safe, simple, and affordable—putting more options in your hands as you grow your family. Explore at PherDal.com.Go to PherDal.com today and use code INFERTILEAF for $10 off.Our Sponsors:* Check out BetterHelp: https://www.betterhelp.comSupport this podcast at — https://redcircle.com/infertile-af-infertility-and-modern-family-building-through-art/donationsAdvertising Inquiries: https://redcircle.com/brandsPrivacy & Opt-Out: https://redcircle.com/privacy
© 2020-2026 Ivy Podcast Discovery LLC
